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ABSTRACT
The School of Graduate Studies
The University of Alabama in Huntsville

Degree ____Doctor of Philosophy _

College/Dept. Biotechnology Science

and Engineering
Name of Candidate Daniel J. Scott Strange
Title Characterization of bacterial peptidyl-tRNA hydrolase 1 from different phylogenetic
clades

Antibiotic resistant bacterial infections have become increasingly difficult to treat
resulting in approximately 23,000 deaths per year in the U.S. alone. Some bacterial
infections, like P. aeruginosa and M. tuberculosis, have become pan- and multi-drug
resistance further limiting treatment options. This has placed an increased demand on the
medical community to find novel antibiotics and novel antibiotic drug targets that can be
used for narrow spectrum inhibition of bacteria. One such target is bacterial peptidyltRNA hydrolase 1 (Pth1). Pth1 recycles tRNA by hydrolyzing the bond between
peptidyl-tRNA and the growing polypeptide chain during abortive translation, thus,
allowing free tRNA to be recycled for future protein biosynthesis. Past studies have
shown Pth1 to be essential to bacterial, but not eukaryotic, life. Where bacteria possess a
single copy of Pth1 in their genome, eukaryotes have a multicomponent tRNA recycling
system that is predicted to compensate for loss of Pth1 function. Likewise, several
previous studies have provided valuable insight into Pth1 structure and dynamics.
However, these studies were limited to single bacterial Pth1 homologs. In contrast, this
study used multiple homologs across phylogenetic space to characterize the in vitro
biochemical properties, kinetic properties, and inhibition profiles from different
phylogenetic clades. This study established three distinct phylogenetic clades with their
own unique characteristics. Importantly, this study also found that both narrow spectrum
activity and small molecule inhibition was possible across phylogenetic space. Thus, this
data further established the attractiveness of bacterial Pth1 as a novel drug target.
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CHAPTER 1

INTRODUCTION

1.1 Current treatments ineffective against antibiotic resistant infections
Antibiotic resistances have emerged to become a major obstacle to treating
bacterial infections. Current treatments have started to become ineffective leading to
septicemia and death. Diseases, like Methicillin-resistant staphylococcal infections,
remain a concern with a minimal number of antibiotics like vancomycin or daptomycin
available. However, several bacteria, like P. aeruginosa, have been shown to be
naturally pandrug- (PDR) or extensively drug resistant (XDR, resistant to all but two or
fewer antibiotics) (Walker, 2019). Elimination of infections associated with multidrug
(MDR), XDR and PDR proved difficult to treat (Magiorakos, 2012). Recently, XDR M.
tuberculosis, the MDR Enterobacteriaceae species S. typhi and E. coli, and PDR P.
aeruginosa were named four of the “scariest superbugs” (McCaughey, 2018). The CDC
estimated over 2 million new antibiotic resistant bacterial infections occur yearly
resulting in 37,000 deaths in the U.S. alone (CDC, 2015). The 20-year stagnation in
discovering new classes of antibiotics or novel drug targets have placed an extra
impetus on addressing this growing concern.
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1.2 Pth1 is a novel drug target
One emerging new target is bacterial peptidyl-tRNA hydrolase (Pth1). Pth1 is a
21-25 kDa enzyme that hydrolyzes the ester bond between peptidyl-tRNA and Nacetylated aminoacyl-tRNA and polypeptide chain, and is responsible recycling tRNA
following abortive translation (Goodall, 2004). Pth1 knockout studies found this to be a
vital enzyme in bacteria, but not eukaryotes (Menez, 2002; Rosas-Sandoval, 2002).
Knockout studies in yeast noticed the non-essentiality in both haploid and diploid cell
lines (Das, 2006). Bacteria have only one copy of Pth1; whereas, eukaryotes have
multiple Pth1-containing domains, Pth1, and a structurally and mechanistically different
Pth2 (Menez, 2002). Likewise, bacterial Pth1s had much lower amino acid consensus
with Homo sapiens Pth1 than seen between different bacterial homologs. Therefore, it
may be possible to selectively inhibit bacterial Pth1s, further lessening impacts of
eukaryotic cells. Given the essential nature of Pth1 in bacteria and the multicomponent
Pth system in eukaryotes, inhibiting bacterial Pth1 is a viable option for antibiotic
development.

1.2.1 Pth1 essential in bacteria
Pth1 was determined to be vital to bacterial life. Loss of Pth1 resulted in tRNA
starvation and cell death (Kabra, 2017). During normal protein biosynthesis, mRNA bind
to the 3’ of the 16S rRNA at the Shine-Dalgarno sequence. Initiation factor 3 (IF-3)
bound to the aminoacyl, or the A-site of the ribosome, recognizes and binds the initiation
codon following the Shine-Dalgarno sequence. This recruits initiation factor 2 (IF-2)
2

complexed with tRNAfMet that complements the AUG codon of the initiation codon.
GDP hydrolysis catalyzes the assembly of the large and small ribosomal subunits, thus
expelling IF-3 and IF-2. GTP hydrolysis of elongation factors (EF) Tu-GTP complex
allows aminoacyl-tRNA to bind to the A site of the ribosome. EF-Ts facilitates the
ribosomal release of EF-Tu-GDP complex and recycles EF-Tu by converting GDP to
GTP. Following this, a peptidyl transferase moves the growing nascent strand to the
tRNA occupying the a site. EF-G:GTP hydrolysis translocates the tRNA in the A-site to
the P-site and moves down one codon on the mRNA in the 3’ direction. The free tRNA
having already transferred its amino acid leaves the ribosome through the exit or E-site.
This continues in a GTP-hydrolysis dependent fashion until a termination codon is
reached. Recognition of a termination codon, UGA, UAA, or UAG, activates release
factor 3 to release the polypeptide chain from the peptidyl-tRNA, or the tRNA
occupying the P-site. The ribosome will then disassociate in a GTP-hydrolysis dependent
fashion. (Clancy and Brown, 2008).
During abortive translation, translation stalls. If this cannot be rescued, the
ribosome will be disassembled, ejecting peptidyl-tRNA, or the tRNA in the P-site still
attached to the nascent polypeptide chain, into the cytosol of the cell. Peptidyl-tRNA
must be cleaved from the bound polypeptides to be recycled for future protein
biosynthesis. In bacteria, Pth1 is the enzyme responsible for hydrolyzing the nascent
polypeptide chain from the peptidyl-tRNA in the cytosol. Without this tRNA recycling
mechanism, bacteria will die due to tRNA starvation, with tRNA tied up and unable to
be used in further protein biosynthesis (Das, 2006).

3

Figure 1.1 Pth1 prevents tRNA starvation: During abortive translation, the ribosome stalls,
disassociates and releases peptidyl-tRNA into the cytosol. Loss of Pth1 function results in tRNA
starvation and eventual cell death.

1.2.2 Inhibiting protein biosynthesis is a proven strategy
Historically, disruption of protein biosynthesis has been demonstrated to be a
proven strategy for antibiotics. Several currently available antibiotics have targeted the
ribosome. These antibiotics achieved bactericidal or bacteriostatic effects through
several mechanisms such as: inhibiting tRNA from entering the A site (tetracyclines),
blocking the peptidyl transferase center (macrolides) (Wilson, 2014). Targeting the
ribosome also has a stoichiometric disadvantage compared to Pth1. It has been
determined there are 1,300 Pth1/cell compared to 10,000 ribosomes in the bacterial cell
(Cruz-Vera, 2000). Therefore, targeting Pth1 also has a stoichiometric advantage
compared to ribosome. Overall, Pth1 inhibition could be used by itself as an avenue for
4

antibiotic development but also shows considerable promise for use synergistically
with known antibiotics that target the ribosome.

1.2.3 Different Pth enzyme families
Based on differences in structure, mechanism and amino acid sequence two
families of Pth enzymes were found: the cytosolic Pth1 and mitochondrial Pth2 families
of enzymes. X-ray structures of Pth1 and Pth2 were demonstrably different with Pth1
retaining the monomeric α/β hydrolase folds. The H. sapiens Pth2 structure revealed a
very different four-stranded antiparallel β-sheet core with two α-helices on either end that
was dimeric in solution (De Pereda, 2004). Mechanistically, Pth1 enzymes differed from
Pth2 in enzymatic reaction and product. Pth1 was determined to cleave the ester bond
between the 3’ OH of the terminal tRNA adenosine and the polypeptide chain, leaving
behind free tRNA and a polypeptide chain. The catalytic triad of Asn10, His20, and
Asp93 as noted in Figure 1.1A differed from H. sapiens Pth2 (Schmitt, 1997). Prior to
discovery of Pth2, a phosphodiesterase was shown to cleave the adenosine from the CCA
acceptor stem of peptidyl-tRNA in rabbit reticulocytes. This enzymatic reaction
recognizes and cleaves tRNAfMet similar to that of S. sulfataricus Pth2, the first Pth2
discovered (Fromant, 2003). This enzymatic reaction hydrolyzes the bond between the
3’-adenosine and 3’-cytosine in the 3’-CCA acceptor stem and created CC-tRNA and
AMP-polypeptide chain reaction products (De Pereda, 2004; Rosas-Sandoval, 2002). The
catalytic triad for H. sapiens Pth2 was determined to be Lys 81, Asp93, and Ser 155
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shown in Figure 1.1B (De Pereda, 2004). As such, loss of Pth1 function in eukaryotes
could be compensated for via structurally and mechanistically different Pth orthologs.

Figure 1.2 Differences in Pth structure and catalytic residues: A.: E. coli Pth1 (PDB: 2PTH),
shown in blue, has a α/ β hydrolase structure of six α helices surrounding a mixed β sheet core
with the catalytic triad of Asn 10, His 20, and Asp93. B.: H. sapiens Pth1 (PDB: 1Q7S), shown
in grey, has an α/ β fold with two helices on either end surrounding four antiparallel β sheets.
The catalytic triad of Lys 88, Asp 145, Ser 155 was found in H. sapiens Pth2.

1.2.4 Elevated production of most tRNAs cannot compensate for loss of Pth1 function
Bacterial tRNA production and maturation are energetically costly, but required to
ensure proper translation (Toh, 2001; Altman, 1975). Multistep maturation, posttranscriptional modifications of tRNA nucleosides, and methylation of nucleotides
throughout the tRNA must be completed prior to protein biosynthesis for tRNA to be
translationally competent (Roh, 2009). Therefore, the bacterial tRNA recycling system is
requisite on Pth1 function. Mature tRNAs are routinely recycled for future protein
6

biosynthesis during normal translation or via Pth1 activity in the case of abortive
translation to avoid tRNA starvation. Lengthy and energetically expensive tRNA
syntheses would be required to compensate for loss of Pth1 function during abortive
translation.
tRNALys has been noted to help maintain low levels of Pth1 in C600 E. coli
cells possessing the Pth(TS) mutant (Cruz-Vera, 2000). As such, tRNALys production
can compensate for loss of Pth1 function. However, deletion of the Pth gene in E. coli
determined tRNALys with other rescue mechanisms, such as tmRNA and RelA, was not
enough to prevent cell death (Singh and Varshney, 2004). Therefore, loss of Pth1 has
been shown to cause cell death suggesting that synthesis of new tRNAs alone was not
be able to prevent tRNA starvation and cell death (Cruz-Vera, 2000). This further
demonstrates the essentiality of Pth1 in bacteria but not in eukaryotes. Eukaryotes can
compensate for the loss of Pth1 and energetic cost of syntheses and maturation of new
tRNAs with Pth1 orthologs and multiple Pth1-containing domains.

1.3 Pth1 structure and dynamics
Pth1’s structure and functionality remain conserved despite variability in their
primary sequences between bacterial and eukaryotic homologs. Several X-ray
crystallography structures have been deposited in the protein database (PDB). Much
attention has been paid to E. coli Pth1 (EcPth1) as this has been the most studied
structurally. However, several other homologs have been studied from such species as V.
cholerae, mycobacterial species M. tuberculosis and M. smegmatis, and P. aeruginosa.
7

Most of the structures have been elucidated from gram-negative or mycobacterial species,
but a handful of Pth1 structures from gram-positive have been determined.

1.3.1 Pth1 structure
Pth1 structure Pth1 has the recognized α/β hydrolase structural motif. Pth1
consisted of a seven-stranded twisted β-sheet core surrounded by six α-helices (Schmitt,
1997; Giorgi, 2011). Although Pth1 retained the fold of other hydrolases, the catalytic
residues were not maintained. Typically, a hydrolase contains a nucleophilic residue,
usually a serine or cysteine, in its catalytic triad (Bischoff, 2012; de Pereda, 2004). The
catalytic cleft, shown in Figure 1.3, was found buried within the β-sheet core consisting
of Asn10, His20, and Asp93 numbered via EcPth1 residues (Schmitt, 1997). The
catalytic triad of Pth1 was conserved across bacterial homologs. Schmitt et al (Schmitt,
1997) discovered His20 was essential for catalytic activity via site-directed mutagenesis
of the catalytic triad in EcPth1 (shown in Figure 1.2). This finding was later confirmed
by two other independent studies (Goodall, 2004; Fromant, 1999).
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Figure 1.3: Pth1 structure: Pth1 maintains the α/β hydrolase fold with six α helices surrounding
a mixed β sheet core. Pth1 has a catalytic triad of Asn10, His 20, and Asp93 (in black) with
putative RNA-binding residues in helix 3, or the base loop (purple) and helix 4, or the lid loop
(yellow). Helix 3 binds the 3’-CCA acceptor stem of peptidyl-tRNA, while helix 4 is
hypothesized to act as a clamp. The gate loop (in blue) has a conserved structural fold.

The proposed mechanism put forth in the literature has been a nucleophilic attack on the
ester bond between the 3’ OH of the ribose and the 3’-adenosine of tRNA by His20. This
cleavage of the ester bond, therefore, allows free tRNA to be recycled for future protein
biosynthesis by cleavage of the ester bond (Figure 1.3).

9

Figure 1.4: Proposed mechanism of peptidyl-tRNA hydrolysis by Pth1: 1. His20 protonation by
water. 2. Hydroxyl anion attack of the ester bond forms an unsTable intermediate. 3. The
unsTable intermediate dissociates into free tRNA and polypeptide chain thus recycling peptidyltRNA for future protein biosynthesis.

Moreover, the conservation of the α/β hydrolase structural motif and these catalytic
residues across orthologs were found amongst orthologous hydrolase enzymes despite
genetic diversity and slight variations in the catalytic pocket itself (Figure 1.4).
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Figure 1.5 Conserved structure of Pth1: This superimposed structure of EcPth1 in blue (PDB
2PTH), SaPth1 in white (PDB 4YLY), MtuPth1 in purple (PDB 2JRC) and PaPth1 in yellow
(PDB 4FYJ) reveal conserved α/β hydrolase fold and gate loop confirmation circled and
highlighted in red.

Putative residues involved in RNA-binding and recognition were further
described (Giorgi, 2011). Conserved Asn21 near helix-1 and Asn68 near helix-2
demonstrably interacted with the 3’-CCA acceptor stem mimic, 3-(L-[N,N-diacetyllysinyl)amino-3-deoxyadenosine (Giorgi, 2011; Kabra, 2017). Residues important in
RNA recognition of the 3’-CCA acceptor stem were found to include Asp96, Gly111,
Asn113, Leu115, Lys116 in or near helix-3. Therefore, the residues near and in helix-3
(Fig 1.2 shown in purple) has been called the binding cleft or the “base loop” (Kumar,
2012; Kabra, 2017). Likewise, the residues Phe146 and Val149 in or near helix-4, or the
“lid loop”, have been revealed to be of putative importance in Pth1:peptidyl-tRNA
interactions using chemical shift perturbation nuclear magnetic resonance spectroscopy
(NMR) with modified tRNA substrate (Giorgi, 2011, Kabra, 2017).
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The Pth1 mutant, Pth(rap), possesses an Arg133His mutation on β7-strand within
the catalytic pocket that makes the mutant temperature sensitive. However, unlike the
Pth(TS), Pth(rap) was shown to have very low specific activity when mutated to a
histidine (Garcia Villegas, 1991; Schmitt, 1997, Cruz-Vera, 2000). This mutation only
recognized specific peptide moieties and was thought to be involved in substrate
recognition. Furthermore, when Pth(rap) mutation was combined with K105A (on β6strand) mutation, Pth1 lost the ability to recognize the 5’-phosphate of peptidyl-tRNA on
the acceptor stem (Fromant, 1999). As such, both Arg133 and Lys105 are thought to be
involved in RNA binding or substrate recognition within the catalytic pocket.
Residues His142 – Leu154 in helix 4 (shown in yellow in Figure 1.2) have
been previously defined as the lid loop (Schmitt, 1997). Similarly, 5’-phosphate
binding residues Lys107, Lys109 and Arg137 have been shown to aid in the proposed
clamping mechanism attributed to helix-4 lid loop (Schmitt, 1997).
The gate loop region of Pth1 has a conserved fold regardless of amino acid
sequence. Residues Leu97 – Val or Lys105 have been defined as the “gate loop”
(Selvaraj, 2007). The Gly101Ala mutation induces temperature sensitivity, causing Pth1
to be inactivated at 42 °C (Menninger 1979; Cruz-Vera, 2000).

1.3.2 Enzymatic dynamics
Previous studies determined Pth1 acts like a clamping mechanism with the lid loop
open in its apo form and binding the 3’-phosphate of adenosine as well as part of the 3’CCA acceptor stem in its closed form (Kabra, 2017; Giorgi, 2011). These previous
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studies performed NMR chemical shift perturbations and relaxation to determine putative
dynamics in both V. cholerae and E. coli Pth1, respectively, to map putative residues
involved in dynamics. Prior to these studies, most comparisons used computational in
silico molecular dynamics (MD) studies to hypothesize the dynamics constraints. The
prevailing hypothesis was the gate loop and the lid loop were inversely correlated to the
dynamics between apo and closed. However, 1H-15N nuclear Overhausen effect (NOE)
NMR relaxation studies performed by Kabra et al. (Kabra, 2017) disproved this
hypothesis. Moreover, these studies revealed the highly flexible α-helices 3 and 4 were
largely responsible for global protein dynamics (Kabra, 2017; Giorgi, 2011; Goodall,
2004). Despite having several residues and highly flexible regions with fast time scale
motion, global protein dynamics were reported to be intermediate time scale motions in
the 2 – 10 ns range (Kabra, 2017).
Global Pth1 dynamics has presented the unique challenge as the 3’-CCA acceptor
stem of peptidyl-tRNA has high flexibility. As such, high resolution Pth1:peptidyl-tRNA
complexed structures are not available currently. Hames et al. (2014) provided a lowresolution small angle neutron scattering complexed structure that confirmed Pth1
recognized and bound the 3’-CCA acceptor stem at the final adenosine. This further
confirmed the previous chemical shift perturbation NMR findings (Giorgi, 2011).
Without a high-resolution complexed structure, global dynamics of Pth1 have proven
difficult to elucidate. However, several studies have provided insight into local protein
regions and individual residues.
Mutational studies within V. cholerae Pth1 showed key conserved residues were
involved in both discernment of peptidyl-tRNA from aminoacylated-tRNA and protein
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dynamics. Giorgi et al. (Giorgi, 2011) determined Asn10 was putatively responsible for
substrate recognition via site-directed mutagenesis of Asn10Asp. Pth1 recognized Naminoacyl-tRNA and peptidyl-tRNA only. Importantly, fMethionyl-tRNAfMet has a
nucleotide mismatch of nucleotide 1 and 72 thus preventing hydrolysis of the initiator
peptidyl-tRNA by bacterial Pth1.
Site-directed mutagenesis of His20 to alanine or asparagine does not alter protein
dynamics significantly. However, H20A and H20N rendered Pth1 catalytically inactive
(Schmitt, 1997; Kabra, 2017, Giorgi, 2011; Goodall, 2004). These previous studies
identified slower mobility in the base loop upon binding of peptidyl-tRNA. Specifically,
Gly111 and Asn113 – Lys116 in or near the α-helix 3 and some α-helix 2 residues were
shown to have slower mobility based on chemical shift perturbations and backbone
NOE relaxation studies (Giorgi, 2011; Kabra, 2017, Selvaraj, 2012). Similarly, residues
near the catalytic His20 residue showed evidence of slower motion (Kabra, 2017).
Alternatively, His 145 and Asp 147 in the lid loop exhibited faster time scale
motion based on NOE relaxation studies. The N- and C- terminus, β3-β4 sheets, and
Asn72 in α-helix 2 also had faster time scale mobility and greater flexibility than the rest
of the regions of Pth1 (Kabra, 2017; Giorgi, 2011). The slower mobility and lowered
flexibility of residues near His20. In silico MD studies and NMR relaxation studies of
flexibility in α-helix 5 and 6 showed similarity in both the computational and
experimental data (Kabra, 2017).
In silico MD simulations have suggested the high degree of lid and base loop
flexibility could be responsible for the mobility of the largely inflexible gate loop and the
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widening of catalytic pocket (Kabra, 2017). Based on slower chemical exchange and
relaxation times, the positioning of the residues near and in base loop have been
hypothesized to bind peptidyl-tRNA as well help to position the ester bonds and nascent
peptide chain for hydrolysis. The faster closing of the lid loop has been proposed to
encapsulate the nascent peptide chain allowing for cleavage of the ester bond between the
3’-adenosine and polypeptides (Giorgi, 2011; Kabra, 2017; Schmitt, 1997). Based on the
in silico MD, chemical shift perturbation NMR mapping, and 1H-15N NOE NMR
relaxation studies performed, the proposed residues involved have been largely identified
and found to be conserved.
It should be noted that most of the Pth1 dynamics studies until now have been
mainly comprised of in silico MD simulations. Only a small number of 1H-15N NOE
NMR relaxation studies exist in the literature. More research will be needed to confirm
the proposed dynamics. However, thus far, global and local in silico MD simulations and
1

H-15N NOE NMR relaxation studies have been qualitatively similar (Kabra, 2017;

Giorgi, 2011).

1.4 Pth1 Kinetics
Pth1 kinetics previously was determined in several watershed Pth1 studies. Three
studies found striking similarities in the kinetics of EcPth1 (Shilock, 1979; Schmitt, 1997;
Goodall, 2004). Every study determined non-native (e.g. cycloaminated or 3’-CCA
mimics such as 3-(L-[N,N-diacetyl-lysinyl]amino-3-deoxyadenosine) had a Km ranging
from 5.5 – 6.0 μM for wildtype EcPth1. Various mutational studies of residues showed
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variations as well, such EcPth1 N68A and N114A. The new Km for these mutations were
12.5 and 3.9 μM, respectively (Fromant, 1999). Interestingly, Goodall et al. (Goodall,
2004) reported significant changes in the Km when catalytic residues were mutated.
Asn10Asp and Asp93Asn mutations resulted in 7.9 and 3.8 μM, respectively. Both
Schmitt et al. (Schmitt, 1997) and Goodall et al. (Goodall, 2004) demonstrated His20Ala
or His20Arg mutations made the enzyme catalytically inactive. As such, kinetic
parameters were unattainable. Further evidence of Asn10Asp using a 3’-CCA mimic to
obtain kinetic parameters resulted in a Km of 0.8 μM for EcPth1 Asn10Asp (Giorgi,
2011). This prompted the hypothesis that N10 was the residue responsible for discerning
N-protected-aminoacyl-tRNA and peptidyl-tRNA from free floating aminoacyl-tRNA.
As these residues are highly conserved, the role in Asn10 in tRNA recognition can be
extrapolated to Pth1 homologs.
Peptidyl-tRNA has been shown to not bind aminoacyl-tRNA unless it is Nprotected. Furthermore, when a monopeptide or monopeptide bound to a 3’-CCA mimic
was used as a substrate, peptidyl-tRNA binding and recognition, as well as kinetic
parameters and hydrolysis, were shown to be greatly reduced (Giorgi, 2011; Schmitt,
1997; Shiloch, 1975). Therefore, Pth1 was determined to show a greater preference for
N,N-diacetyl or dipeptide nascent chain lengths compared to N- protected-monopeptide
bound tRNA. Using acylmono- to hexapeptide nascent lengths, Pth1 kinetics becomes
faster after dipeptide and increased until a tetrapeptide length. Km values decreased from
72 μM for N-block acetylated Val-tRNA (AcVal-tRNA) and Gly-Val-tRNA to 17 μM for
(Gly)3-Val-tRNA (Shiloch, 1975). Vmax was also found to increase from 3.5 pmol/min
to 42 pmol/min for AcVal-tRNA and (Gly)3-Val-tRNA respectively (Shiloch, 1975).
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Polypeptide chain length equal to or greater than a tetrapeptide were determined to have
consistent kinetic parameters. As it can be ascertained from EcPth1, kinetic parameters
are dependent on nascent polypeptide length up to a tetrapeptide.

1.5 Summary of current study
Past studies probed the potential of Pth1 as a novel antibiotic and its structural
characteristics in a single homolog. While the aim of this research was also to expand
upon the antimicrobial potential of Pth1, the scope of this research included
characterizing the similarities and differences between bacterial homologs. The current
study explored three areas: characterization of phylogenetic clades and their respective
inhibition profiles, characterization of kinetic parameters across phylogenetic space,
and characterization of nucleotide specificity in relations to phylogenetic clades.

1.5.1 Phylogenetic characterization
Bacterial Pth1 homologs have a wide genetic distribution and consensus between
homologs were demonstrably low. These characteristics have not previously been
explored and could greatly impact the ability for Pth1 to be a novel drug target. Multiple
X-ray crystallography and solution NMR structures were derived largely from grampositive or mycobacterial species. Similarly, molecular docking studies both differed in
results and binding strength depending on which docking program was used. Also, the
docking studies were computational without any in vitro validation. In this current
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research, bacterial homologs from across phylogenetic clades were accessed to
ascertain whether the large genetic distribution would greatly alter the characteristics of
each homolog and their respect clades. These characteristics were comprised of
phylogeny, expression, gram-specificity, and solubility. An inhibition screen against
EcPth1, P. aeruginosa Pth1 (PaPth1), S. typhimurium Pth1 (StPth1), M. tuberculosis
Pth1 (MtuPth1), S. aureus Pth1 (Sa Pth1) and B. cereus Pth1 (BcPth1). The results for
both can be found in chapter 3.

1.5.2 Characterization of kinetic parameters across phylogenetic space
Despite structural conservation and high conservation within clades, kinetics
analysis frequently only addressed EcPth1 kinetic parameters. Several mutational studies
assayed differences between wildtype and mutant EcPth1, but little to no data on different
homologs have been published. This project obtained and analyzed the kinetic parameters
of five wild-type homologs and one mutant homolog: EcPth1, PaPth1, MtuPth1, BcPth1,
SaPth1, and SaPth1 E99P. These five homologs were representative of at least one
homolog per clade with two clades having two different homologs. The results have this
investigation will be presented in chapter 4.
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1.5.3 Nucleotide inhibition
During this current project, it was discovered EcPth1 was weakly inhibited by
adenosine triphosphate (ATP) using in vitro assays. ATP was selected due to the 3’-CCA
acceptor stem of tRNA. Likewise, adenosine was previously reported to be the only thing
needed for Pth1 to bind a 3’-CCA mimic. Sixteen nucleotides were screened for
inhibition against EcPth1, StPth1, and SaPth1. While further in vitro screening against
Homo sapiens Pth1 (HsPth1) and Homo sapiens Pth2 (HsPth2) were required, the results
of nucleotide inhibition screen against bacterial Pth1s can be found in chapter 5.

19

CHAPTER 2

METHODS

2.1 Background
Described in this chapter is the phylogenetic characterization between bacterial
Pth1 clades as well as general methodology for Pth1 purification and natural product
plant extract (NPPE) inhibition screens used to verify inhibition characteristics
between orthologs of bacterial Pth1. Although several X-ray crystal structures exist of
different homologs of Pth1, little is known about similarities and differences between
individual homologs and phylogenetic clades.

2.2 Methods
Described below are the methods used to characterize similarities and
differences between phylogenetic clades by using NPPE inhibition screens of Pth1
homologs, Michaelis-Menten kinetics studies, and nucleotide inhibition.
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2.2.1 Phylogenetic determination of Pth1
Several hundred bacterial Pth1 sequences of medical significance was aligned
using the multiple alignment sequencing tool MUSCLE using EcPth1 as a reference, and
using four H. sapiens Pth1sequences, S. solfataricus, H. sapiens, and A. fulgidus Pth2 as
outgroup members. Sequences were empirically scored for conservation and formatted
into a phylogenetic tree using freely available EMBL tools. Any conservation score
under 0.25 was not considered. The phylogenetic tree was constructed using neighborjoining without distance corrections algorithm found on the EMBL website. Any
duplicate sequences were removed prior to determination of phylogeny.

2.2.2 Pth1 growth and expression optimization
Apart from M. tuberculosis Pth1 (MtuPth1), all Pth1 homologs were cloned into a
N-terminus his-tagged pKQV4 vectors with carbenicillin resistance. MtuPth1 was in
pRESTB vector with carbenicillin resistance (Selvaraj, 2006). Pth1 vectors were
transformed into BL21 E. coli competent cells on LB plates with 20 μg/mL carbenicillin.
A 3 mL starter culture was grown overnight in a shaking incubator at 180 rpm at 37 °C.
The starter culture was transferred to 30 mL with same media and under same conditions
until an OD600 of ~0.6 was reached. The culture was transferred to 1 L of LB with 0.2
μg/mL carbenicillin. The culture reached an optimal OD600 for each homolog and was
induced with appropriate concentration of IPTG as noted in Table 2.1 below. The
induced culture was placed in a shaking incubator at the appropriate temperature for the
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optimal time and aeration rate for each Pth1 homolog. Since no induction temperature
for MtuPth1 was included in the literature, MtuPth1 was induced at the temperature for
its genetically closest homolog M. smegmatis Pth1 ( Selvaraj, 2006). Cells were
harvested using centrifugation at 20,000 xg rpm for 15 minutes and stored at -80 °C
until ready to use. Samples were taken prior to and after induction to confirm expression
on 12% SDS-PAGE gel.

Pth1
Homolog

Vector/Antibi Growth
otic
Media

Aeratio
n

[IPTG]

Induction
OD600

Induc
tion
Time
(hr)

B. cereus

pKQV4/carb
enicillin
pKQV4/carb
enicillin
pRESTB/car
benicllin
pKQV4/carb
enicillin
pKQV4/carb
enicillin
pKQV4/carb
enicillin

2X M9

1:4

1 mM

0.7

LB

1:4

1 mM

LB

1:4

LB

1:4

LB

1:8

LB

1:4

E. coli
M.
tuberculosis
P.
aeruginosa
S. aureus
S. typhi

Antibiotic
Amount

16

Inducti
on
Tempe
rature
(°C)
37

0.6

6

37

1:1,000

0.5
mM
1 mM

0.6

16

27

1:1,000

0.6

16

18

1:1,000

0.5
mM
1 mM

0.9

16

14

1:2,000

0.8

3

37

1:1,000

1:1,000

Table 2.1 Pth1 growth and induction conditions

2.2.3 Pth1 purification
Frozen, pelleted cells, transformed were thawed and resuspended in a 20 mL
Buffer A, see Table 2.2 (typically in 50 mM NaHPO4, pH 7.4, 300 mM NaCl buffer) per
original liter of cell culture. Cells were incubated with 15 mg lysozyme for 30 mins at
room temperature, followed by sonication (5 secs on, 5 secs off for 5 mins). The lysate
was separated into soluble supernatant and insoluble pellet using centrifugation 20,000 xg
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for 30 mins Samples of total, supernatant and pellet were taken, heated for 15 mins, and
run on 12% SDS-PAGE gel to determine the solubility.
Supernatant, containing soluble protein, was loaded onto a freshly charged Histrap nickel column for metal chelation affinity chromatography. Purification buffers used
were: Buffer A (50 mM NaHPO4, pH 7.4, 300 mM NaCl) and Buffer B (50 mM
NaHPO4, pH 7.4, 300 mM NaCl, 150 mM Imidazole) unless otherwise specified in Table
2.2. His-tagged Pth1 was bound to His-Trap Nickel column and washed with 21 mM
imidazole and 33 mM imidazole. His-tagged Pth1 was eluted off the column with 150
mM imidazole. MtuPth1 did not fully elute with 150 mM imidazole and required 200 –
250 mM imidazole for elution. Selvaraj et al (2006) used 500 mM imidazole for eluting
MtuPth1. The purification buffers were: Buffer A (20 mM Tris-HCl, pH 7.5, 100 mM
NaCl, 10% glycerol) and Buffer B (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10%
glycerol, 500 mM imidazole) (Selvaraj, 2006). The elution buffer was modified to have
only 250 mM imidazole. Fractions were analyzed on 12% SDS-PAGE gel. Those
fractions with His-tagged Pth1 were pooled and buffer exchanged against buffer needed
for each Pth1 homolog as seen in Table 2.2. Purified his-tagged Pth1 was concentrated
using ultracentrifugation and stored at 4 °C until ready to access activity using an acid
urea-minigel (Holloway, 2015).
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Table 2.2: Pth1 homolog purification and buffer exchange conditions
Pth1 Homolog

Buffer A

Buffer B

[Imidazole]
required for
Elution
150 mM

B. cereus

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl, 150 mM
Imidazole

E. coli

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl, 150 mM
Imidazole

150 mM

M. tuberculosis

20 mM Tris-HCl,
pH 7.5, 100 mM
NaCl, 10% Glycerol

20 mM Tris-HCl, pH
7.5, 100 mM NaCl,
10% Glycerol, 500
mM Imidazole

≥ 150 mM

P. aeruginosa

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl

150 mM

S. aureus

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl, 150 mM
Imidazole
50 mM NaHPO4,
pH 7.4, 300 mM
NaCl, 150 mM
Imidazole

S. typhi

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl

50 mM NaHPO4,
pH 7.4, 300 mM
NaCl, 150 mM
Imidazole

150 mM

150 mM

Buffer
Exchange
Buffer
25 mM
NaHPO4, pH
6.0, 250 mM
NaCl, 2 mM
DTT at 4 °C
10 mM TrisAcetate, pH 8.0

20 mM TrisHCl, pH 7.5,
100 mM NaCl,
2 mM βmercaptoethanol
20 mM BisTris, pH 6.6,

25 mM
NaHPO4, pH
6.0, 250 mM
NaCl, 2 mM
DTT
10 mM TrisAcetate, pH 8.0

2.2.4 Peptidyl-tRNA extraction
C600 TS E. coli cells were grown to isolate nascent peptide peptidyl-tRNA. At 30
°C, Pth1 in the C600 TS E. coli cells is active; however, at 42 °C, Pth1 is inactive
allowing for accumulation of peptidyl-tRNA (Varshney, 1991). A 5 mL starter culture of
C600 TS E. coli cells in LB were grown at 30 °C with no antibiotics until an OD 600 of 0.6
at 180 rpm in a shaking incubator. The culture was transferred to 30 mL LB culture
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under the same conditions. The 30 mL culture was transferred to 100 mL LB and grown
to an OD600 of 0.4. C600 TS E. coli culture was induced at 42 °C for 70 mins, rapidly
cooled and harvested at 20,000 xg for 15 mins. Cell pellets were stored at -80 °C for a
minimum of 24 hours for optimal peptidyl-tRNA extraction.
Following a published protocol, C600 TS E. coli cell pellets were resuspended in
0.3 mM NaOAc, pH 5.2, 10 mM EDTA. Phenol extractions with resuspended cells in
1:1 ratio was carried out, and sonicated for 5 secs, 5 secs off for 5 mins (Varshney, 1991).

Lysate was separated from insoluble organic layer via centrifugation at 1,100 xg for 5
mins. The aqueous layer was taken, and this phenol extraction was repeated. Following
the final phenol extraction, lysate was chloroform extracted, and separated with
centrifugation at 1,100 xg for 5 mins. The aqueous layer was removed, and ethanol
precipitated with absolute ethanol in 1:2.5 ratio. Ethanol precipitation was repeated three
times prior to aliquoting 500 μL of bulk peptidyl-tRNA into Eppendorf tubes.
Centrifugation at 26,000 xg and sterile air drying were used to remove an excess ethanol.
Peptidyl-tRNA was stored at -80 °C. Each batch was tested for consistency in intensity
on urea-PAGE assay. Bulk peptidyl-tRNA was quantified using the UV
spectrophotometer absorbance at A260, and an A260/A280 ratio was assessed for purity of
the peptidyl-tRNA extraction. A typical peptidyl-tRNA extraction yielded a
concentration of ~28 – 30 μM per aliquot. Uniform gel intensity and peptidyl-tRNA
concentration were important for an accurate analysis of Pth1 activity and inhibition
when using urea-PAGE.
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2.2.5 Pth1 Activity
Reactions varied only in the amount of Pth1 present to determine the
concentration needed for each assay. The concentration needed was defined as the
concentration that had equivalent activity to 3 μL of 30 μL EcPth1. Reaction volumes
were 20 μL and contained varying concentrations (0.5 – 4 μL of 30 μL Pth1). To this
was added, 3 μL of 30 μM bulk peptidyl-tRNA, 5 μL of 4X Buffer B (40 mM TrisAcetate, pH 8.0, 40 mM magnesium acetate, 80 mM ammonium acetate) and DEPCtreated water to reach a total reaction volume. The positive control using 30 μL EcPth1
was used to standardize all assays. The negative control with no Pth1 was also used to
aid in quantification during urea-PAGE analysis. The reactions were quenched after 30
minutes.
Likewise, Pth1 activity was analyzed for kinetics using time course assays. The
reaction volume remained the same; however, 3 μL of 30 μL mg Pth1 was used
without any changes with respect to the rest of the reaction set-up. Each reaction was
quenched every 5 minutes until 30 minutes was reached using with a urea loading dye
(100 mM sodium acetate, 35 mM urea, 0.0025 g bromophenol blue, DEPC-treated
water to 5 mL total volume). Reactions were run on 8 M urea-PAGE and analyzed for
differences in migration of peptidyl-tRNA between controls and samples.
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2.2.6 Urea-PAGE
Following the protocol of Holloway et al. (Holloway, 2015), 6 M urea-PAGE gels
were run for ~2.5 hours at 100 V with 100 mM NaOAc, pH 5.2 running buffer. All lanes
were pre-run and rinsed to remove any residual urea from the wells. For better resolution,
gel electrophoresis box was packed in ice to help maintain a running temperature of 6 –
10 °C. Urea gels were stained with 0.3 g methylene blue in 0.5 M NaOAc for 3 hours.
After 3 hours, urea gels were destained with deionized water for approximately 30 mins
to remove any excess stain. Destained urea gels were imaged allowing for densitometric
analysis.

2.2.7 Urea-PAGE Analysis
Analysis of the acid urea-minigels was performed using the published protocol
(Holloway, 2015). The distance cleaved peptidyl-tRNA (positive control) and uncleaved
peptidyl-tRNA (negative control) migrated was compared to the migration of the
peptidyl-tRNA in the sample (Holloway, 2015). This comparison allowed a quick,
inexpensive, and less toxic way to analyze the percentage of cleaved peptidyl-tRNA in
NPPE samples by setting positive control to equal 100% cleavage and negative control
to equal 0% cleavage. Therefore, the following equation can be used:
(

−

=

)÷(

−

Percent inhibition was obtained from 100 % – percent cleaved.
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)

100%

2.2.8 Site-directed mutagenesis
The Agilent QuickChange Lightning kit protocol was to mutate residues in the
SaPth1 gate loop. The following primers for each homolog in their respective pKQV4
vectors:
SaPth1 E99P Fwd:
5’TTAAGCGAACTTGTCCTTGTGGTAAATCTAAATCATCATATAAGACAATTAAATCT
TCTGG 3’

SaPth1 E99P Rev:
5’CCAGAAGATTTAATTGTCTTATATGATGATTTAGATTTACCACAAGGACAAGTTCG
CTTAA 3’
SaPth1 Q100P Fwd:
5’ TTTTTGTCTTAAGCGAACTTGTCCTGGTTCTAAATCTAAATCATCATATAAG 3’
SaPth1 Q100P Rev:
5’ CTTATATGATGATTTAGATTTAGAACCAGGACAAGTTCGCTTAAGACAAAAA 3’
SaPth1 Q102V Fwd:
5’ CGCACTTCCTTTTTGTCTTAAGCGAACAACTCCTTGTTCTAAATCTAAATCATCATA
3’
SaPth1 Q102V Rev:
5’TATGATGATTTAGATTTAGAACAAGGAGTTGTTCGCTTAAGACAAAAAGGAAGTGG
CG 3’

PCR products were restricted with DpnI and ligated using T4 DNA Ligase provided with
the Agilent kit. Ligations were transformed into DH5α E. coli competent cells and plated
on LB-carbenicillin plates. Resulting colonies were grown overnight in a 5 mL LB
culture (5 μL carbenicillin). Transformants were harvested using centrifugation at 20,000
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xg, and plasmid DNA was extracted using GeneJET plasmid miniprep kit. Plasmids
were sequenced to confirm site-directed mutagenesis.
Transformations of SaPth1 mutants were repeated in BL21(DE3) E. coli
competent cells. Transformants for each mutation were grown overnight and transferred
to 30 mL cultures as previously described. Following this, the SaPth1 mutants were
transferred into equal 500 mL volumes under optimized wild-type SaPth1 expression
conditions and EcPth1 expression conditions as noted in Table 2.1. However, induction
OD600 of 0.9 and temperature was maintained. The cells were harvested and placed in -80
°C until purification. Purification conditions were unchanged from Table 2.2. Those
purifications that yielded soluble protein were quantified using UV spectrophotometry at
280 nm, and activity was confirmed using 8M acid urea-minigels.

2.2.9 Natural product plant extract (NPPE) inhibition screen
56 NPPE obtained from North Queensland, Australia, Monteverde, Costa Rica,
Matabeleland, Zimbabwe; and Abaco Island, Bahamas were graciously provided by Dr.
William Setzer’s research group (Listed in Appendix A). Lyophilized fractions were
resuspended in DMSO and 1% w/v solvent. These extracts were then accessed for
inhibition against EcPth1, PaPth1, StPth1, MtuPth1, SaPth1, and BcPth1. 20 μL
reactions were prepared using positive and negative controls as previously described.
The reaction set up for NPPE screen was: the concentration needed to equal that of 0.63
mg EcPth1 (usually 3 – 4 μL of 0.63 mg Pth1), 5 μL 4X buffer B, 4 μL of NPPE, 3 μL of
30 μM bulk peptidyl-tRNA, and DEPC-treated H20 for a total reaction volume of 20 μL.
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Each NPPE was incubated with Pth1 for 5 minutes prior to addition of peptidyl-tRNA.
Reactions were quenched after 30 minutes and run on a 6 M acid urea-minigel. UreaPAGE analysis was carried out.

2.2.10 Pth1 kinetics
Pth1 was diluted to a concentration of 30 μM with DEPC-treated water. PeptidyltRNA was quantified using A260/A280 ratio to be 30 μM. Reactions as described above
were carried out at 1:0.1.3, 1:0.25, 1:0.5, 1:1, 1:2, 1:3, and 1:4 Pth1:peptidyl-tRNA molar
ratio. These reactions were quenched at 5 - 10 minute intervals ending at 30-50 minutes
dependent on substrate concentration. Reactions were run on 8 M urea gels and analyzed
as stated above. Percent cleaved multiplied by the initial substrate concentration was
equal to product concentration. Michaelis-Menten product versus time curves were
plotted in Excel. The slope of the tangent line of the curve at time zero was equivalent to
the Vo at that substrate concentration. This assay was repeated in triplicate for all time
intervals and peptidyl-tRNA concentrations used. Vo was averaged and plotted with their
respective standard deviations represented as the error bars. Following this, a Wilkinson
non-linear regression was performed using Excel to determine the least squares to best fit
the data (Wilkinson, 1961; Duggleby, 1995). Provisional kinetic parameters were
estimated using sum of least squares for determined Vo and initial substrate concentration
(So). The parameters were further refined using calculations to minimize the least squares
of the Michaelis-Menten equation and the first derivative with respect to Km using the
provisional kinetic parameters. The Michaelis-Menten equation was then used
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to determine expected values using the refined parameters from the nonlinear
regression analysis. These values were fitted to the observed velocities for each
substrate concentration, and Solver function was used to further minimize the
summation of the squared error. Pearson correlation analysis of the observed and
expected velocities for each So to find coefficient of determination. This was to ensure
the quality of the fit between expected and observed velocities.

2.2.11 Nucleotide inhibition screen
16 nucleotides were screened against EcPth1, StPth1, and SaPth1. The assay
followed the same protocol as 2.2.4, however 4 μL of 100 mg/mL nucleotide
concentration (final reaction volume of 20 mg/mL) was incubated with Pth1 for 5
minutes prior to addition of peptidyl-tRNA for initial quantitative screen. Assays were
quenched at 30 minutes followed by urea-PAGE, and urea-PAGE analysis. Any
nucleotides yielding inhibitory results were tested quantitatively to determine the
concentration at which 50% inhibition (IC50) was observed. Decreasing concentrations of
nucleotides were achieved by using a 1:1 dilution. 4 μL of each concentration (100
mg/mL, 50 mg/mL, 25 mg/mL, 12.5 mg/mL, 6.25 mg/mL, 3.13 mg/mL) was incubated
with 30 μM Pth1 prior to addition of 30 μM peptidyl-tRNA to a total 20 μL final reaction
volume. The final nucleotide concentrations in the reaction were 20 mg/mL, 10 mg/mL, 5
mg/mL, 2.5 mg/mL, 1.3 mg/mL, and 0.63 mg/mL, respectively. Each reaction was
quenched after 30 minutes. Urea-PAGE analysis was as in section 2.2.8 to determine the
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percent cleaved and percent inhibition for each inhibitory nucleotide concentration. Each
nucleotide concentration was run in triplicate.

32

CHAPTER 3

PHYLOGENETIC CHARACTERIZATION OF PTH1 CLADES

3.1 Background
With the emergence of antibiotic-resistant bacterial infections being of great
concern, new drug targets to combat these diseases are of utmost importance. One such
target is Pth1. Pth1 functions to cleave the nascent chain of peptides from peptidyl-tRNA
during abortive translation (Goodall, 2004). Previous studies have shown that loss of
function of Pth1 leads to tRNA accumulation and cell death in bacteria (Kabra, 2017).
Many current antibiotics target protein biosynthesis, and as such, has been shown to be an
effective antibiotic strategy.
However, very little is known about how these vital enzymes differ between
bacterial species. To address this gap in knowledge, Pth1 sequences from pathogenic
bacterial species were aligned allowing for phylogenic characterization. Subsequently,
Pth1 enzymes from each clade were recombinantly expressed and had purification
conditions optimized and characterized. These same Pth1 enzymes were assayed for
inhibition using a common set of 56 NPPE. In addition and augmenting the phylogenetic
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characterization, described in this chapter are the growth conditions and the patterns of
inhibition observed from these NPPE inhibition screens.

3.2 Results and Discussion
Three distinct clades emerged from phylogeny of bacterial Pth1 with their own
biochemical characteristics. These three clades were accessed for the similarities and
differences in levels of expression, purification yields, and the possibility of achieving
broad spectrum, narrow spectrum, or clade specific inhibition. The three clades are
defined as: the E. coli-like clade, herein referred to as Clade 1; the M. tuberculosis-like
clade, referred to as Clade 2; and the S. aureus-like clade, referred to as Clade 3.

3.2.1 Pth1 Phylogeny
To date, only a handful of Pth1 homologs have been extensively studied. Most
findings have been limited to EcPth1 or MtuPth1. It was hypothesized based on these
results most Pth1 homologs behaved similarly due to the conserved structure (Kabra,
2016). However, this current project confirmed that Pth1 homologs were not the same
with regards to phylogeny or biochemical characteristics. Phylogenetic analysis allowed
for homologs across phylogenetic space to be identified and studied.
Clade 1 homologs were highly conserved. EcPth1 showed high similarity with
PaPth1 and StPth1, respectively. These enzymes only differ in 9 and 13 residues out of
190-194, respectively, when compared to EcPth1. It was of note that these residue
changes were usually synonymous to one another, such as an aromatic phenylalanine
for an aromatic tyrosine. Clade 2 Pth1 homologs similarly showed high sequence
34

conservation (80% identity) within the clade. In comparison, Clade 3 showed less
conservation within its respective clade, with only ~ 40% conservation of sequence
identity. Clade differences were apparent when conservation, any substitution that
preserves the physiochemical properties of the residue, which was approximately 60%
conservation between clades. Likewise, the identity between clades was 35 – 40 %
identity. The conservation between bacterial homologs, even between clades, was much
higher than when bacterial homologs were compared to human sequences. Only 30 – 40
% sequence homology exists between bacterial and human Pth1 homologs. HsPth1 was
more closely related to the structurally and mechanistically different HsPth2 than to any
bacterial homologs.
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Figure 3.1 Phylogenetic tree of Pth1: Pth1 is divided into three distinct clades based on gram
specificity. Clade 1 consisting of Pth1 homologs from gram negative bacteria. Clade 2 largely
consists of mycobacterial Pth1 homologs; while Clade 3 Pth1 are made up of Pth1 homologs
from gram positive bacteria.

3.2.1.1 Gram specificity
As Figure 3.1 shows, Pth1 phylogeny was found to separate according to the
bacterial species gram-status. Pth1 homologs from gram-negative bacteria like P.
aeruginosa, S. typhi, and E. coli were shown to make up the content of Clade 1. Clade 3
Pth1s were found to be from gram-positive bacteria, such as S. pneumoniae, S. aureus,

36

and S. pyogenes. Pth1 from mycobacterial species, which have both gram-negative and
gram-positive characteristics, formed Clade 2 (Fu and Fu-Liu, 2002).
One possible explanation for the gram-specificity of Pth1 homologs could be due
to the differences in tRNA, 16S rRNA and 23S rRNA methylation patterns for gramnegative, and gram-positive species (Klagsbrun, 1973). Both E. coli and P. aeruginosa
tRNA contained 1-methylguanine, 7- methylguanine, ribothymidine, and 2methyladenine (Klagsbrun, 1973). In contrast, gram-positive species were found to also
have 1-methyladenine in their tRNA. Based on this, Pth1 could have diverged with
respect to gram-status to accommodate for the differences in methylation of tRNA.
Clearly, Clade 3 homologs recognized and cleaved peptidyl-tRNA extracted from E. coli
C600 TS cells. As such, Clade 3 homologs do not require 1-methyladenine to recycle
peptidyl-tRNA in vitro, and the chemistry of the reaction does not change. The
phylogenetic gram-specificity could potentially explain why Clade 3 homologs had more
favorable binding affinity for bulk peptidyl-tRNA than EcPth in terms of their kinetics
(discussed in further detail in chapter 4). Pth1 has been shown to tightly interact with the
TψC arm of peptidyl-tRNA where 1-methyladenine is found at A58 (Hames, 2014).
Other enzymes, such as aminoacyl-tRNA synthetases, are known to need the appropriate
tRNA methylation for enzymatic activity or substrate recognition (Guenther, 1994). It
has been hypothesized that Pth1’s tight interaction could potentially be involved in
substrate recognition (Hames, 2014). The gram-specificity of Pth1, tRNA methylation
and modifications, and rRNA modifications lends credence to this hypothesis.
In comparison, gram-specificity did not play a significant role in small molecule
or nucleotide inhibition. The residues in the catalytic cleft of Pth1 were highly
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conserved. Likewise, structure and predicted mechanism were conserved across
phylogenetic space evidenced by the Vmax parameters (discussed further in chapter 4).
Any tRNA modifications would likely not affect catalytic residues in the catalytic cleft.
Past studies found that alterations in these catalytic residues affected activity, but not
substrate binding (Giorgi, 2011; Goodall, 2004). As such, small molecule inhibition
would likely involve interaction with these residues (discussed in chapter 5). Future
work is required to determine if Clade 1 homologs would have reduced or no activity in
the presence of 1-methyladenine tRNA. Likewise, Clade 3 homologs would also need to
be screened for differences in activity when peptidyl-tRNA, or N-acetylated tRNA, from
a gram positive species were used.

3.2.2 Biochemical characterization of Pth1 clades
Several X-ray crystal and NMR structures of Pth1 have helped to determine key
residues in Pth1, such as the catalytic triad of Asn10, His20, and Asp93 or putative RNA
recognition and binding sites (Schmitt, 1997; Goodall, 2001, Giorgi, 2011). His20 was
demonstrated to be the catalytic residue (Schmitt, 1997). Kinetic and structural studies of
EcPth1 and V. cholerae Pth1 have shown helix 3 acts as a receiving lip pushing peptides
into the catalytic pocket. Helix 4 is thought to act as a clamp that closes about the
adenosine in the 3’-CCA acceptor stem and nascent polypeptide chain. Low resolution
structures exist helping to form an understanding of the peptidyl-tRNA orientation with
respect to Pth1 when complexed (Hames, 2014). These key residues, shown in Figure
3.2, are well conserved between bacterial homologs.
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Figure 3.2 Catalytic binding pocket of Pth1: Residues
from the catalytic triad of E. coli Pth1 (PDB:2PTH)
Asn10, His20, Asp93 are highlighted in red. α-helix
4, shown in yellow, has been shown to have RNA
binding and recognition residues. This is thought to
act as a clamping mechanism to help achieve
cleavage via the His20 residue.

Although Pth1 homologs all function to cleave peptide from peptidyl-tRNA during
abortive translation, differences in expression and solubility make purifying and
crystallizing homologs very difficult. The PDB database shows most of Pth1 crystal
structures come from either the E.coli-like or M. tuberculosis-like clades, therefore most
of the current knowledge in structure and enzymatic actions are derived from these two
clades.

3.2.2.1 Pth1 growth and general trends associated with phylogenetic clades
It should be noted that as recombinant Pth1 growth was performed using
different amino acid sequences or plasmids that a direct comparison could not be made.
These general growth trends were considered more correlative, and could have resulted
from any number of cellular, metabolic, or plasmid constraints placed on E. coli BL21
competent cells. Clade 1 Pth1 homologs had greater expression than that of Clade 2 and
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Clade 3 Pth1s. MtuPth1, a clade homolog, had the least expression of the all homologs
tested under optimized conditions. The Clade 3 homologs, SaPth1 and BcPth1, showed
more expression when grown under their optimized conditions.

Figure 3.3 Expression differences between clades: The blue arrow (noting Pth1) shows the
differences between clades after induction. The Clade 2 homolog, MtuPth1 (in blue) showed the
least amount of expression. Clade 1 homologs (in black) had the most expression of all three
clades.

As can be seen in Figure 3.3, most Clade 1 Pth1 homologs produced greater
yields of soluble protein with standard growth, and induction conditions with respect to
aeration rate, IPTG and antibiotic concentrations (as previously shown in Table 2.1). Of
note, PaPth1 has a C-terminus truncation of the last 10 residues resulting in the noTable
molecular weight difference. This truncation does not affect activity. Similarly, Clade 2
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Pth1s required 1:4 aeration rate, 1 mM carbenicillin, 500 μM IPTG, overnight
incubations, and 27 °C induction temperature. As stated previously, growth conditions
for MtuPth1 were ascertained from Selvaraj et al (Selvaraj, 2006) with induction
temperature obtained from the closely related M. smegmatis Pth1 (Kumar, 2012). It was
noteworthy that Kumar et al. (Kumar, 2012) used 300 μM IPTG to induce transformed
bacterial cultures. The general trend from this and previous studies was that Clade 2
homologs required more optimization of induction conditions than Clade 1 homologs,
but significantly less optimization of growth, expression and purification conditions than
Clade 3 Pth1s. As such, Clade 2 homologs were intermediate with regards to
optimization of growth conditions. However, it should be noted that Clade 2 homologs
were cloned into a different plasmid. As such, this was a general correlative trend. In
stark contrast, Clade 3 Pth1s had significantly different growth conditions even between
homologs within its own clade. BcPth1 growth was not aeration rate dependent but 2X
M9 minimal media was required for optimum expression (Taylor-Creel, 2014). However,
antibiotic and IPTG concentrations were identical to Clade 1 Pth1s. The growth
conditions for SaPth1 presented in Table 2.1 deviated from previously published sources
(Bonin, 2002). SaPth1 required an aeration rate two times greater, and longer, slower
induction at lower temperatures. Any deviation from these conditions resulted in very
little to no soluble protein following sonication. Growth conditions of other Clade 3
homologs like S. pyogenes Pth1 (SpPth1) with X-ray crystal structures were known, but
not used in this current study (Singh, 2014). Although aeration rates for SpPth1 was not
noted in Singh et al. (Singh, 2014), their growth and expression conditions were
correlated with slower incubation times at lower temperatures. Therefore, based on
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growth conditions, Clade 2 was found to be an intermediate between Clade 1 and Clade
3. Although Clade 2 shared similarities with Clade 3 Pth1s, homologs in Clade 3 were
discovered to produce a far lower yield with little or no allowance for deviation in these
conditions. Clade 3 homologs also needed individualized optimization. Each
homologous enzyme tested often necessitated considerable optimization. Although these
were correlative, this could provide insight to future optimization of expression and
purification for novel bacterial Pth1 homologs in the future.
These findings also illustrated why very few Clade 3 Pth1 crystal or solution
NMR structures exist in the PDB to this point as well further illustrated the differences
both between and within clades. Optimization of growth, expression, and purification of
Clade 3 enzymes proved cumbersome. Unlike Clade 1 or Clade 2 homologs, Clade 3 did
not have similar conditions between the homologs tested so far for optimal yields of
soluble protein (Taylor-Creel, 2014). Stark differences were seen in these conditions in
the literature with some requiring specialized media like terrific broth that increased
solubility (Bonin, 2002). Even under optimized conditions, Clade 3 Pth1 purification
yields were relatively low in comparison to Clade 1 and Clade 2 Pth1 with significantly
less time as both soluble and active. SaPth1 had the lowest yields of soluble protein and
required the greatest amount of optimization.

3.2.2.2 Shared motifs within clades
To improve SaPth1’s solubility and purification yields, amino acid sequences for
Pth1 homologs from across phylogenetic space were aligned to determine any potential
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regions or residues that might account for the difficulties in obtaining soluble
recombinant protein. One noTable difference was the residues in the gate loop region
surrounding G101. Clade 1 Pth1’s had a characteristic Pro-Pro-Gly-Val sequence, as
seen in Figure 3.4A. Clade 2 Pth1’s, likewise, shared had a Glu/Asp-Phe-Gly-Arg motif
around the G101 residue. Clade 3 Pth1 homologs had a mostly conserved Glu/Asp-GlnGly-Gln motif around the G101 residue. The gate loop region housing the G101A
mutation responsible for temperature sensitivity in EcPth1. Temperature sensitivity was
hypothesized to cause aggregation thereby affecting its solubility (Garcia-Vilegas, 1991,
Cruz-Vera, 2000). Similarly, the gate loop structure was highly conserved despite
differences in amino acid sequence (Figure 3.4B). As such, the gate loop region was
assessed to determine its effect on Pth1 solubility in SaPth1.

Figure 3.4: Gate loop region of bacterial Pth1: A: Multi alignment sequencing of the gate loop
region revealed a conserved motif within phylogenetic clades. B: The gate loop structured
maintained a highly conserved fold following superimposition of crystal structures.
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3.2.2.3 Site directed mutagenesis of SaPth1 gate loop affects solubility
Site directed mutagenesis of SaPth1 gate loop was performed to increase the
soluble yields of recombinant Pth1 obtainable from homologs that required significant
optimization to express and purify nominal yields as this would be both time-saving and
cost-effective. For an easier comparison, EcPth1 residue numbering was used with
regards to the SaPth1 gate loop mutations. Gate loop mutations affected solubility both
positively and negatively. For instance, SaPth1 E99P significantly increased solubility in
both WT SaPth1 and EcPth1 expression conditions. Mutating glutamate to proline
proved to overcome previous aeration rate and IPTG rate dependence seen in wildtype
SaPth1 expression. Purified yield was 4.8 ± 0.2 mg for WT SaPth1 expression conditions
and 1.6 ± 0.1 mg for EcPth1-like growth conditions (as noted in Table 3.1).

Table 3.1: SaPth1 gate loop mutations soluble protein yield
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Alternatively, SaPth1 Q101V was soluble only at the WT SaPth1 expression conditions.
SaPth1-like growth conditions yielded 1.5 ± 0.1 mg following purification and
concentration of protein.The Q101V mutation did not have an affect solubility or
increase the yields obtained (Figure 3.5). In stark contrast, SaPth1 Q100P was largely
insoluble for both growth conditions.

Fig 3.5 Site directed mutagenesis of SaPth1 gate loop affects solubility: SaPth1 E99P yielded the
most soluble protein and was no longer aeration rate or IPTG-concentration dependent. SaPth1
Q102V had some soluble when grown and expressed at wildtype SaPth1 conditions (labeled 1:8
in figure). SaPth1 Q100P was not soluble under wildtype SaPth1 or wildtype EcPth1 (labeled 1:4
in figure).

Firstly, this demonstrated insolubility in SaPth1 and possibly other Pth1s could be
resolved via mutating negatively charged Glu or Asp residues to Pro in the gate loop.
This was consistent with phylogeny as the homologs easier to work with contained at
least one Pro in its gate loop (Fig 3.4). The gate loop of MtuPth1 and other Clade 2
homologs was either Asp or Glu-Phe-Gly-Arg. Likewise, most Clade 3 homologs also
had an Asp or Glu as the first residue within the gate loop followed typically by a ValGly-Lys. The gate loop was the only area not as stochastic in residue differences
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between clades or even individual homologs. Likewise, as can be gleaned from Fig 3.4,
the gate loop structure was highly conserved. The Pro-Pro-Gly-Val motif appears to be
more energetically favorable in this confirmation as Pro is dihedrally more constrained
than other amino acids. However, this would be less ideal for Glu-Phe-Gly-Arg or GluVal-Gly-Lys as this was energetically unfavorable for both glutamate, phenylalanine and
glycine bonds being forced into a static fold most suiTable for prolines. Previous
dynamics data reinforces that the gate loop was not a highly dynamic region (Kabra,
2016).

Figure 3.6 SaPth1 Q100P disrupts salt bridge: A: EcPth1’s gate loop showed no interactions
with helix 5. B:A salt bridge between SaPth1 Glu 154 in helix 5 and Gln 100 in the gate loop
was shown in the X-ray crystal structure (PDB: 4YLY). Disruption of the salt bridge between
Glu 154 and Gln 100 (based on EcPth1 residue numbering) likely led to little solubility when
SaPth1 Q100P was grown.
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A comparison of crystal structures between EcPth1 and WT SaPth1 showed the
Gln100 residue to undergo hydrogen bonding with Glu154 in helix 5 (Figure 3.6). This
salt bridge was unique to SaPth1 based on the available crystal structures.
SaPth1 Q100P likely failed to produce soluble protein due to the loss of this stabilizing
salt bridge between Q100 and E153 in helix 5. This salt bridge was unique to SaPth1 of
the superimposed structures of Pth1 (Fig 3.6b).

3.2.3 NPPE inhibition screen
Natural products have proven a robust source for antibiotics. Similar strategies
have been employed with drug discovery and bioactive fractionation studies to varying
levels of success (Nothias, 2018). This present study did not seek to identify the
compound, or compounds, responsible for inhibition, but to further highlight the
similarities and differences that exist between the clades. As such, these NPPE were
heterogenous mixtures extracted in different solvents. Importantly, the assay described in
Holloway et al (2015) could successfully screen for inhibition regardless of solvent
system used. While only screened against six Pth1 enzymes, narrow spectrum and clade
specific inhibition emerged among the six enzymes tested.

3.2.3.1 Pth1 inhibition
Using an array of NPPE, inhibition was screened for Pth1 inhibition across
phylogenetic space. In particular, Pth1 homologs from E. coli, S. typhimurium, P.
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aeruginosa (Clade 1), M. tuberculosis (Clade 2) B. cereus, and S. aureus (Clade 3) were
included. Figures 3.7 shows a tabulation of the inhibitory profiles for each homolog.

Figure 3.7 Patterns of Pth1 inhibition for the top 25 inhibitory NPPE: Clade 1 Pth1 species
showed a pattern of broad spectrum and clade specific inhibition. P. aeruginosa Pth1 showed
some species specific inhibition but tended to follow the emerging trend of mostly broad
spectrum and clade specific inhibition. Clade 2 was inhibited by both Clade 1 and Clade 3
natural product plant extracts as well as those not seen in Clade 1 or Clade 3.

3.2.3.1.1 Narrow spectrum inhibition possible across phylogenetic space
With some NPPE, Pth1 inhibition strictly followed the clade boundary as for.
Ardisia compressa, Mandevilla veraguasenis, Exothea paniulata, and Inga sierra (extract
numbers 3,4,5, and 6, respectively in Figure 3.7 and Appendix A) which was only inhibitory
within Clade 1 enzymes and the intermediate Clade 2 homolog, MtuPth1. Extracts from
extracts 15. Acacia aulacocarpa, 16. Ocotea floribunda, and 18. Urera caracasma (extract
numbers 15, 16, and 18, respectively in Figure 3.7 and Appendix A)
48

demonstrate narrow spectrum inhibitory activity against just PaPth1 within Clade 1.
Similarly, Albizia adenocephala inhibits BcPth1 and MtuPth1 (extract number 14 in
Figure 3.7). Likewise, SaPth1 showed narrow spectrum inhibition, but at a much greater
occurrence than BcPth1. Where BcPth1 was inhibited by one narrow spectrum extract,
SaPth1 was inhibited in a narrow spectrum fashion by ten other NPPE (Figure 3.7 extract
numbers: 19. Psychotria parvifolora 25. Grevilla lilliana, 21. Cinnamomum tonduzii, 22.
Syzygium johnsonii, 23. Ocotea species from Los llama, 25. Grevilla lilliana, 26.
Neolitsea dealbata (listed in Appendix A), 40. Cryptocarya corrugate (listed in
Appendix A), 55. Bursera (listed in Appendix A), and 56. Bocconia fruitescens (listed in
Appendix A)). This provided the first indication that narrow spectrum inhibition was
possible. Again, it must be kept in mind that the inhibitory activity may not be due to a
single component, but the potential for small molecule inhibition is clear. Even with the
high degree of sequence similarity, differences in the active site exist and lead to
differential small molecule inhibition based on findings from nucleotide inhibition
(discussed further in chapter 5).
Interestingly, Pth1 from P. aeruginosa and M. tuberculosis were inhibited by the
most extracts yet bacterial infections of P. aeruginosa in humans are extremely difficult
to treat due to natural pan-drug resistances. Both P. aeruginosa and M. tuberculosis have
commonly been found in soil. Past studies have shown selective pressure from natural
and antimicrobial sources to drive pan- and multi-drug resistances in both species.
(Lopez-Causape, 2018; Palomino and Martin, 2014). This present study has identified
several novel narrow spectrum inhibitors of PaPth1 and MtuPth1 that could potentially
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inhibit P. aeruginosa and M. tuberculosis, given the compound(s) responsible
for inhibition can be discovered.
With the understanding that natural product extracts are heterogeneous mixtures,
several distinct patterns of inhibition were observed. In some cases, broad spectrum
inhibition of all Pth1 tested was observed. Thus, broad spectrum inhibition was possible.
In recent years, the pharmaceutical and medical industries have started to move away
from broad spectrum antibiotics. Broad spectrum inhibition has been noted for the
increased colonization of and infection by C. difficile as well as increases in antibiotic
resistances (Schäffler, 2018). For this reason, pharmaceutical companies have
overlooked Pth1 as a viable drug target. It was assumed due to the vital function of Pth1
that Pth1 would only cause broad spectrum inhibition. However, this current project
confirmed narrow spectrum or clade specific inhibition of Pth1 were possible in all
homologs tested. Therefore, this brought greater promise to bacterial Pth1 being a novel
antibiotic drug target because narrow spectrum inhibition was observed in all the
homologs tested.

3.2.3.2 Patterns of Inhibition throughout clades
The patterns of inhibition that emerged between Clade 1, Clade 2, and Clade 3
fits the phylogenetic data. Specifically, Clade 2 Pth1s were inhibited by inhibitors narrow
spectrum or clade specific inhibitors of Clade 1 and narrow spectrum inhibitors of Clade
3. However, outside of the Clade 2 Pth1 enzyme tested, these inhibitors were limited to
their respective clades. Like mycobacteria sharing traits of both gram-negative and
gram-positive bacteria, mycobacterial Pth1 was inhibited by both gram-negative Pth1only
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(Clade 1) and gram-positive only (Clade 3) inhibitors of Pth1. This further illustrated
Clade 2 being an intermediate clade mixed with, but closer related to Clade 1 Pth1s. For
example, Inga sierra, Ocotea floribunda (Clade 1), Syzygium johnsonii and
Cinnamomum tonduzii (Clade 3) had observed inhibition in MtuPth1.
Clade 1 had the most susceptibility to NPPE inhibition. Broad spectrum, narrow
spectrum and some clade specific inhibition was observed in Clade 1 homologs. Clade 3
homologs showed the least susceptibility. These homologs demonstrated little broad
spectrum inhibition in the presence of NPPE. As such, Clade 3 homologs had
characteristically more narrow spectrum inhibition observed. These findings demonstrate
the potential not only for broad spectrum inhibition, but also narrow spectrum. It seemed
probable the lowered substrate affinity discussed in chapter 4 played a large role in the
inhibition profiles of each phylogenetic clade.

3.2.3.3 Further qualitative clade characterizations
To further characterize the clades, it was noted that Clade 1 homologs typically
had far greater yields than homologs from Clades 2 or 3. This was due to the solubility
and ease of purifying Clades 1. Clade 1 homologs typically yielded 3.5 – 5 mg per liter
of cell culture. However, PaPth1 did produce 33 mg from a 4 L cell culture. Clade 2
homologs yielded 1.5 – 2 mg of soluble enzyme per liter of cell culture. While
approximately 1.3 – 1.5 mg of soluble protein could be purified from a 1 L culture of
Clade 3 homologs. Clade 3 homologs required the most optimization and were
significantly harder to express and purify than clades 1 or 2. Again, as there were
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differences in plasmids or plasmid DNA sequences, these were also seen as largely
correlative.

3.3 Conclusions
This study discovered three distinct phylogenetic clades which could be exploited
in the development of antibiotics that selectively inhibit an individual Pth1 homolog. The
distinct clades based on sequence alignment showed gram-specificity. Pth1 showed
divergence and diversity in its phylogeny. Three distinct clades, defined above, emerged
with stochastic residue changes throughout their sequence that do not cause any
significant changes in overall charge interactions apart from the gate loop region. These
residues were mainly aromatic residues, such as phenylalanine and tyrosine, to aliphatic
residues, such as leucine, glycine, and alanine. Despite this, key catalytic and putative
RNA-binding residues in the catalytic pocket and helices 3 and 4 were highly conserved
among all homologs screened. As such, the chemistry of the reaction was not altered as
established by the kinetic parameters and small nucleotide inhibition (in chapter 4 and 5).
In contrast to their chemistry, biochemical and phylogenetic characteristics were
quite different. Phylogeny fell along on gram-specific lines. This trend was supported by
previous results regarding gram-specific tRNA and rRNA modifications (Fu and Fu-Liu,
2002; Klagbrun, 1973; Guenther, 1994). Clade 1 homologs derived from gram-negative
bacteria were generally more soluble and susceptible to inhibition than Clade 2 or Clade
3 homologs. The ease of which Clade 1 homologs were expressed and purified also
explained why Clade 1 Pth1 are overrepresented in protein databank. MtuPth1, a Clade 2
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homolog, was an intermediate clade of Clade 1 and Clade 3 homologs with respect to
gram-status, solubility, inhibition, and kinetics, but not expression. This was indeed an
emerging theme throughout this project. Conversely, Clade 3 homologs required the
most optimization to produce minimal yields of soluble protein and was the least
susceptible to NPPE inhibition. This clade was mostly inhibited in a narrow spectrum
fashion.
Importantly, all homologs were susceptible to narrow spectrum inhibition. As
more antibiotic-resistant infections have emerged, the use of broad spectrum
antibiotics has been discouraged. Broad spectrum antibiotics were known to hasten the
rate of antibiotic-resistance in bacteria. Therefore, antibiotic drug targets capable of
narrow spectrum inhibition have a greater clinical importance and a better chance of
development compared to those drug targets only capable of broad spectrum inhibition.
As such, the narrow spectrum inhibition observed provided further evidence that
targeting bacterial Pth1 would be a viable means of potentially treating bacterial
infections. Furthermore, this could potentially be used synergistically with other
antibiotics that also inhibit protein biosynthesis or alone as there is a stoichiometric
advantage of targeting Pth1 over the ribosome
Likewise, HsPth1 was shown to be phylogenetically closer to HsPth2 than any
bacterial Pth1 homolog. Therefore, it seemed likely that HsPth1 would retain the
structure and chemistry of Pth1, but not the same biochemical characteristics, such as
expression and solubility and inhibition. Thus, inhibition of a bacterial homolog might
not inhibit HsPth1 as evidenced by the diversity in inhibition profiles through
phylogenetic space.
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While most of the data from biochemical and phylogenetic characterization
sought to further the attractiveness of Pth1 as a novel antibiotic drug target, site directed
mutagenesis of the gate loop region determined mutating aspartate/glutamate to proline
could rectify solubility issues within certain homologs. This knowledge could pave the
way to structurally study or identify inhibitors to less soluble bacterial Pth1 homologs
in the future.
In conclusion, these findings further demonstrated the attractiveness of Pth1 as a
novel drug target. Pth1 had three distinct, gram-specific phylogenetic clades. These
clades behaved biochemically different with regards to expression, solubility, and
inhibition with Clade 2 being intermediate between the very different Clade 1 and Clade
3 homologs. It was previously believed Pth1inhibitors would only produce broad
spectrum inhibition. However, this project showed that narrow spectrum inhibition was
possible, and selective targeting of individual Pth1 homologs was plausible in the future.
These two findings were of the greatest significance for antibiotic development because
broad spectrum antibiotics are known to increase the rate of antibiotic resistance
clinically. As a novel antibiotic drug target, Pth1 showed more promise because
individual Pth1 homologs could be accomplished with narrow spectrum inhibition. As
well, biochemical and kinetic differences can be exploited to selectively target individual
Pth1 homologs. Furthermore, this project established that more difficult homologs could
have their solubility increased via glutamate to proline mutation in the gate loop of Pth1.
This would allow for future structural or kinetic studies and inhibition screens on difficult
Pth1 homologs from medically relevant bacteria to occur more easily.
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Chapter 4

Pth1 Kinetics

4.1 Background
Pth1 kinetics has been well researched in Clade 1 Pth1s, specifically EcPth1.
Previous experiments have shown variation in polypeptide chain length alters kinetic
parameters up to tetrapeptide length (Shiloch, 1975). As the nascent polypeptide chain
length increases, Vmax decreases while Km increases (Shiloch, 1975). After tetrapeptide
length, kinetics parameters of 17 μM and 42 pmol/min for Km and Vmax, respectively,
remained relatively consistent (Shiloch, 1975).
Whereas previous studies focused on a single homolog this project’s scope
allowed for a broader interpretation of Pth1 kinetics. This current project was the first to
compare kinetic parameters of multiple Pth1 homologs spanning phylogenetic space.
However, interpretations of this data must be bounded by the limited number of
homologs from each clade that were tested: one Clade 1 Pth1 (EcPth1), one Clade 2 Pth1
(MtuPth1) and two Clade 3 Pth1s (BcPth1 and SaPth1). The inclusion of EcPth1,
MtuPth1 and SaPth1 have the additional benefit of previous existing kinetic literature for
55

comparison. BcPth1 kinetic analysis using bulk peptidyl-tRNA, performed by a previous
graduate student in this research group, was also included to provide a more robust
characterization of Clade 3 Pth1 kinetics (Taylor-Creel, 2014). Similarly, previous
unpublished values of EcPth1 were used solely for the purposes to verify the accuracy of
the Wilkinson least squares non-linear regression employed in this project prior to use in
the analyses of MtuPth1 and SaPth1 (Wilkinson, 1961).
The vast majority of the previously reported studies used diacetyl-lysyltRNALys as Pth1 was found to have the greatest affinity for this partial substrate to all
other peptidyl-tRNA species (Menninger, 1973). Bulk peptidyl-tRNA was used for each
Pth1 homolog for this project allowing for a more complete understanding of Pth1
kinetics in its native state. Naturally, only a relative comparison can be made between
this study and previous studies using diacetyl-lysyl-tRNALys.
Similarly, bulk peptidyl-tRNA extracted from C600(TS) E. coli cells would have
polypeptide chain lengths that were not limited to just N-acetylated-dipeptidyl-tRNAs.
Hence, one could reasonably assume a stochastic distribution between N-acetylatedpeptidyl-tRNA to tetrapeptide chains or greater where Vmax has been empirically
determined to remain consistent (Shiloch, 1975). Substrate affinity was also determined to
increase as peptide length increased. Thus, Pth1 would have a greater likelihood of
hydrolyzing peptidyl-tRNA with longer polypeptide chains at a constant rate. For this
reason, steady state assumptions were used in determination of kinetic parameters.
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4.2 Results and Discussion
Kinetics parameters were identified using bulk peptidyl-tRNA for Pth1 homologs
representative of all three clades. Well studied homologs were selected as comparisons
could be made to results in the published literature. When possible, previous data using
full substrate were included into this current project as is the case with BcPth1 (TaylorCreel, 2014). The results obtained were found to be consistent with those studies
previously published using bulk peptidyl-tRNA but differed from those using
radiolabeled isotopes or 3’-CCA mimics in absolute terms, but consistent in relative
terms.

4.2.1 Verification of nonlinear regression analysis
Percentage of cleaved peptidyl-tRNA from the in vitro activity assay (section
2.2.10) was multiplied by the peptidyl-tRNA concentration to determine the amount of
cleaved peptidyl-tRNA for each time interval. Data were then averaged for the triplicate
measurement, and a standard deviation was determined. The error bars in Figure 4.1
were representative of the standard deviation of the averaged cleaved peptidyl-tRNA
concentration. An initial estimate of Vo was obtained by finding the slope of the tangent
line at time zero for each peptidyl-tRNA concentration. An example of the cleaved
peptidyl-tRNA versus time plot used for Vo determination can be found in Figure 4.1.
Unlike previous figures from this current project, black, green, and blue are used to
indicate different initial bulk peptidyl-tRNA concentrations, So, rather than to
differentiate between clades. Red, black and blue represented a S o of 28 μM, 56 μM, and
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112 μM peptidyl-tRNA, respectively. Initial Vo for EcPth1 were 1.2 μmol/min, 2.7
μmol/min, and 3.5 μmol/min for a So of 28 μM, 56 μM, and 112 μM peptidyltRNA, respectively.

Figure 4.1 Vo determination of EcPth1: Initial Vo for EcPth1 was determined at each bulk
peptidyl-tRNA concentration. The slope of the tangent line at time zero was equal to Vo for that
substrate concentration.

Nonlinear regression of kinetic parameters has been demonstrated to be more
accurate than linearized analyses. For this reason, experimentally determined Vo for each
substrate concentration were analyzed using a least squares nonlinear regression first
described by Wilkinson et al (Wilkinson, 1961). Velocity and substrate concentrations
were the only data needed to obtain provisional kinetic parameters using Wilkinson least
squares nonlinear analysis. This analysis used can be seen in Tables 4.1. Wilkinson
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least squares nonlinear analysis was chosen as this was the standard kinetic analysis in
the literature, and what many more labor intensive, computational kinetic approximations
have sought to improve.
Table 4.1: Determination of Provisional E. coli Pth1 Kinetic Parameters

Provisional kinetic parameters were refined using least squares of the Michaelis-Menten
equation and the first derivative with respect to Km as seen in Table 4.2. This analysis
method was verified against previously unpublished EcPth1 kinetic data using bulk
peptidyl-tRNA performed by a previous graduate student in this research group prior to
expanding this method to other homologs. Previous results were determined to be Vmax
of 4.5 ± 0.1 μmol/min and Km of 40.0 ± 3.0 μM. Representative analyses of each clade
(MtuPth1 and SaPth1) can be found in Appendix B.
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Table 4.2: Determination of E. coli Pth1 Kinetic Parameters

Following nonlinear regression analyses, the Vo for each So concentration were
plotted. Further refinement of kinetic parameters was carried out using the substrate
Vmax and Km determined from the Wilkinson nonlinear regression to estimate
expected values to fit a curve to experimentally derived values (seen in blue in Figures
4.2, 4.3, and 4.4). These expected values were plotted using the Michaelis-Menten
equation, and refinement using the solver function on Excel was performed to further
minimize the least squares. The slower rate seen in the curves at later time intervals
were due to the lack of substrate as free tRNA was greater than that of bulk peptidyltRNA. As more peptidyl-tRNA was cleaved, less substrate was present for catalysis as
Pth1 will only hydrolyze peptidyl-tRNA or N-protected acyl-aminoacyl-tRNA. This
trend was seen throughout all kinetic analysis presented in this chapter.
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4.2.2 Kinetic parameters across clades
This current project sought to characterize kinetic parameters across phylogenetic
space. As previously mentioned, the homologs selected were the most studied from each
phylogenetic clade. The Wilkinson nonlinear regression analysis was used on EcPth1,
MtuPth1, and SaPth1 to estimate kinetic parameters. Previous results from BcPth1 were
included in this current project allowing for a slightly more expanded interpretation of Clade
3 homologs as this study also used bulk peptidyl-tRNA (Taylor-Creel, 2014).

4.2.2.1 Clade 1 Pth1 kinetic parameters
EcPth1, a Clade 1 homolog, was found to have a Vmax of 5.1 μmol/min ± 0.1
μmol/min and a Km of 51.0 μM ± 3.0 μM. Kcat was approximated to be 3.0 x 10-3 s-1.
This resulted in a catalytic efficiency (Kcat/Km) of 6.3 x 10-5 μmol-1*s-1. The R2 value
of 0.99 from the nonlinear regression fit was significantly higher than the linearized R 2
value of 0.83 from the original fit. This was indicative that the nonlinear regression
utilized provided a better fit and kinetic approximations compared to the previous
linearized model using an integrated Michaelis-Menten equation.
EcPth1 had the highest Km of all homologs tested even when the partial
substrate diacetyl-lysyl-tRNALys was used. Previous Km estimates remained consistent
between 5.5 – 6.0 μM for wildtype EcPth1 in vitro (Giorgi, 2011; Kabra, 2017; Goodall,
2004; Schmitt, 1997). Higher Km values indicated a weaker affinity to form an enzyme61

substrate complex (Robinson, 2015). No matter if partial or full substrate were used in
kinetic analysis, Km values for EcPth1 were consistently weaker than others reported
(Giorgi, 2011; Shiloch, 1975; Goodall, 2004; Bal, 2007; Bonin, 2002). Thus, decreased
affinity for partial or bulk peptidyl-tRNA was seen as a trend, and served as further
validation of EcPth1’s kinetics parameters in this project. Evidence of a higher K m value
could also be established from the less defined parabolic fit of the data seen in Figure 4.2
and Figure 4.3 compared to MtuPth1’s fit (Figure 4.4) and SaPth1’s fit (Figure 4.5).

Figure 4.2 Nonlinear regression fit of EcPth1 kinetics: EcPth1 rate data (in red) was fit with
the expected values (in blue) using Vmax and Km obtained from the nonlinear regression and
So concentrations. These yielded an R2 value of 0.99 between the actual and expected data.
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While EcPth1 had the lowest substrate affinity, it did not have the lowest catalytic
efficiency. Kinetic analysis of PaPth1, the other Clade 1 homolog tested, yielded similar
results to EcPth1 with a Vmax of 5.0 ± 0.9 μmol/min, Km of 47 ± 0.9 μM, a Kcat of 3.0
x 10-3 s-1, and a catalytic efficiency of 6.3 x 10-5 μmol-1*s-1 (Figure 4.3 and Table 4.3).
PaPth1 was the least efficient enzyme kinetically out of all the homologs tested. Both a

general trend that substrate affinity and catalytic efficiency were decreased in
both homologs in comparison to Clade 2 or Clade 3 homologs.

Figure 4.3 Nonlinear regression fit of PaPth1 kinetics: PaPth1 rate data (in red) was fit with values (in
blue) using Vmax and Km obtained from the nonlinear regression and So concentrations.
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4.2.2.2 Clade 2 Pth1 kinetic parameters
The Clade 2 homolog, MtuPth1, was found to have a Km of 17.0 μM ± 1.3 μM, a
Vmax of 5.3 μmol/min ± 0.2 μmol/min (Figure 4.3). Kcat and Kcat/Km for MtuPth1
were 3.2 x 10-3 and 1.9 x 10-4, respectively (Table 4.3). The nonlinear regression fit had
a R2 value of 0.96. While the Vmax was similar to that of EcPth1, its Km was three times
less than that of EcPth1. This meant that the overall biochemical reaction was consistent
between EcPth1 and MtuPth1. This was expected due to the high conservation of the
structural folds and catalytic residues. No previous Vmax data existed in the literature.
Thus, Vmax results from this project could not be compared to past studies.

Figure 4.4 Nonlinear regression fit of MtuPth1 kinetics: MtuPth1 data (in red) was fit with
the expected values (in blue) using Vmax and Km obtained from the nonlinear regression and
So concentrations. This fit produced an R2 value of 0.96.
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A Km of 0.7 μM was found by measuring the hydrolysis of tritium labeled
diacetyl-[3H]-lysyl fromtRNALys (Bal, 2007). The difference in results likely stemmed
from different the methodologies in obtaining kinetic parameters and nascent polypeptide
length. Residues radiolabeled with tritium or other radioactive isotopes could provide
much greater sensitivity, and therefore could easily account for the differences in the data
between this project and the previous project (Randerath, 1970). Despite this, both Km
values were within micromolar range.
MtuPth1, showed similar results to previously published kinetics of Clade 3
homologs using full substrate (Taylor-Creel, 2014). MtuPth1 kinetic parameters,
specifically its Km value, was intermediate of Clade 1 homologs and Clade 3
homologs. While the chemistry of each homolog tested was similar, the substrate
affinity differed across phylogenetic space. Thus, MtuPth1 had 33% greater substrate
affinity than EcPth1.

4.2.2.3 Clade 3 Pth1 kinetic parameters

Kinetic parameters for Clade 3 homologs have been sparse in the literature to
date. Past studies were limited to fluorophore labeled partial substrate using a different
assay in the case of SaPth1. However, results previously published from this research
group were used for BcPth1 (Taylor-Creel, 2014). There were no differences between
the assay or substrate used allowing for direct comparisons to be made. Parameters for
BcPth1 were 5.5 ± 0.3 μmol/min and 8.0 ± 1.0 μM for Vmax and K m, respectively.
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SaPth1 kinetic parameters were 6.0 ± 0.1 μmol/min and 10.0 ± 1.0 μM for Vmax and K m,
respectively. Kcat and Kcat/Km were 3.6 x 10-3 s-1 and 3.6 x 10-4 μmol-1*s-1 (Table 4.3)
indicating greater substrate affinity, turnover rate, and catalytic efficiency than Clade 1
and Clade 2 homologs.

Figure 4.5 Nonlinear regression fit of SaPth1 kinetics: SaPth1 rate data (in red) was fit with
the expected values (in blue) using Vmax and Km obtained from the nonlinear regression and
So concentrations. This fit produced an R2 value of 0.99.

The fit for SaPth1 kinetics was found to be 99% correlated to the expected values (as
noted in Figure 4.5). Vmax for SaPth1 was 0.5 μmol/min faster than BcPth1. However,
BcPth1 had slightly more affinity to peptidyl-tRNA than SaPth1. Km values were with
2.0 μM of one another (Table 4.3).
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Previous studies of Clade 3 Pth1 homologs have been limited in their scope.
Previous work in our research group demonstrated the kinetic parameters of BcPth1 to be
a Vmax of 5.5 μmol/min and a Km of 8 μM using bulk peptidyl-tRNA (Holloway, 2015;
Taylor-Creel, 2014). Other studies on SaPth1 using diacetyl-[3H]-lysyl-tRNALys found
kinetic parameters in the micromolar range however significantly smaller values of
Vmax of 0.13 μmol/min and Km of 2.8 μM were reported (Bonin, 2002).
Kinetic analysis was also carried out on the SaPth1 E99P mutant to determine the
gate loop mutations’s impact on SaPth1 kinetics. Kinetic analysis was not carried out on
SaPth1 Q100P due to the loss of solubility. Likewise, kinetic analysis of SaPth1 Q102V
as this mutation did not yield any difference in solubility from WT SaPth1. SaPth1 E99P
Vmax and turnover values were both very similar (Figure 4.6). Therefore, site directed
mutagenesis of the gate loop region did not affect the overall chemical reaction.
However, Km and Kcat/Km of SaPth1 E99P decreased by half to 20.0 ± 1.7 μM and 1.8 x
10-4 μmol-1*s-1, respectively. As such, mutating aspartate to proline in the gate loop
region of SaPth1 resulting in half the substrate affinity and catalytic efficiency of WT
SaPth1, and was more similar to the intermediate Clade 2 homologs kinetic
characteristics with respect to Km and Kcat/Km.
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Figure 4.6 Gate loop mutation affects Km but not Vmax: WT SaPth1 (red circles) was compared
against SaPth1 E99P. Vmax was consistent between WT and the mutant, however the Km for
SaPth1 E99P was double that of WT SaPth1.
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Table 4.3 Kinetic Parameters between clades
Pth1 Homolog

Vmax

Km

Kcat

Kcat/Km

(μM*min-1)

(μM)

(s-1)

(μmol-1*s-1)

E. coli

5.1 ± 0.1

51.0 ± 3.0

3.0 x 10-3

5.9 x 10-5

P. aeruginosa

5.0 ± 0.1

47.0 ± 0.9

3.0 x 10-3

6.3 x 10-5

M. tuberculosis

5.3 ± 0.2

17.0 ± 2.2

3.2 x 10-3

1.9 x 10-4

S. aureus

6.0 ± 0.1

10.0 ± 0.4

3.6 x 10-3

3.6 x 10-4

B. cereus*

5.5 ± 0.3

8.0 ± 1.0

3.3 x 10-3

4.1 x 10-4

*Denotes values previously published using full substrate

As, such Km values from this and previous studies were consistently in micromolar range
despite the differences in substrate. Any decrease in substrate affinity between partial and
full peptidyl-tRNA substrate was likely due to the differences in assays and increased
length in the nascent peptide chain as previously noted.
Clade 3 homologs hydrolyzed peptidyl-tRNA faster, but the Vmax and Kcat were
consistent with those from Clade 1 and Clade 2. As such, the chemistry across
phylogenetic space was similar. This was an expected result given the highly conserved
structure and catalytic residues across phylogenetic space. Clade 3 homologs had the
greatest substrate affinity among the three clades using bulk peptidyl-tRNA.
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4.2.3 Comparison of Pth1 clade kinetics
As can be ascertained from Table 4.3, Vmax only varied slightly between the
clades. Vmax is defined as the maximum velocity an enzymatic reaction can attain when
the enzyme is fully saturated with a substrate. The Clade 1 homologs, EcPth1 and
PaPth1 had the lowest Vmax throughout the clades (Figure 4.7). Thus, at saturation,
EcPth1 and PaPth1 had the slowest rate of reaction. SaPth1 was found to have the
highest Vmax. However, these values were within a 1.0 μmol/min range. Larger
variations were seen in Vmax when compared to past results, such as the increase of
MtuPth1 (Bal, 2007).

Figure 4.7 Comparison of kinetics from different phylogenetic clades: SaPth1 (in black)
representative of Clade 3 homologs had a greater Vmax, Kcat, and Kcat/Km than the intermediate
Clade 2 homolog, MtuPth1 (in green), and Clade 1 homologs, EcPth1 (navy blue) and PaPth1
(blue).

However, this likely arose from differences in assay type and use of partial
substrate (Figure 4.7). The Michaelis constant, Km, represents the concentration (in
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molarity) when rate is half of the Vmax. As such, a higher Km has a less favorable
binding with its substrate and requires greater substrate concentration to reach its
Vmax. As such, the enzyme has different rates dependent on substrate concentration
due to different levels of saturation. Alternatively, a lower Km means the enzyme has
more favorable binding to its substrate. This would also require lower substrate to
achieve saturation. For this reason, enzymes possessing a lower Km typically have a
more consistent rate due to their being saturated. As such, Km has also been described
as its substrate affinity, or how favorably an enzyme will bind to its substrate
(Robinson, 2015). In this project, EcPth1 Km value was found to be 15% greater than
BcPth1, 20% greater than SaPth1, and 33% greater than that of MtuPth1. Therefore,
EcPth1 had less favorable binding to peptidyl-tRNA than Clade 2 and Clade 3
homologs. This was evident from the Similarly, MtuPth1’s K m was 47% and 58%
greater than the Km for BcPth1 and SaPth1, respectively.
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Figure 4.8 Comparison of Km from different phylogenetic clades: Substrate affinity and catalytic
efficiency was greater in Clade 3 homologs with clade 1 homologs having the lowest substrate
affinity and catalytic efficiency. Clade 2 was intermediate of Clade 1 and Clade 3 with respect to
Kcat, Km, Kcat/Km, and Vmax.

Based on these findings, the homologs tested from Clade 2 and Clade 3 had an
increased for affinity for peptidyl-tRNA compared to EcPth1. This was consistent with
other findings in the literature. Previous studies using partial substrate found EcPth1 had
consistently lower substrate affinity (Giorgi, 2011; Schmitt, 1997; Goodall, 2004).
Likewise, MtuPth1 and SaPth1 were found to have greater affinity for peptidyl-tRNA
even when a partial peptidyl-tRNA substrate was used (Bal, 2007; Bonin, 2002).
Homologs from Clade 2 and Clade 3 have consistently shown greater affinity towards
peptidyl-tRNA than EcPth1 both in the literature and this current project. It is of note
that the SaPth1 E99P mutant determined perturbations in the gate loop would, at least in
part, substantially decrease substrate affinity.
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This also further demonstrated that MtuPth1 was intermediate of the Clade 1 and
Clade 3 homologs. MtuPth1 had less affinity towards peptidyl-tRNA than Clade 3
homologs, BcPth1 and SaPth1. However, MtuPth1 had greater affinity towards peptidyltRNA than the Clade 1 homolog, EcPth1. Likewise, the Vmax of MtuPth1 and EcPth1
were closer to each other than the Clade 3 homologs.

4.3 Conclusions
This was the first study to compare the kinetic parameters of the different
clades using full substrate. Prior to this knowledge of Pth1 kinetics was derived largely
from EcPth1. These results showed that phylogenetic clades behave differently from
one another while maintaining structural and mechanistic conservation, just like the
trends observed in gram-specificity, expression and solubility, and inhibition profiles.
One such insight was Vmax for each homolog tested were similar. The hydrolytic
residues and structural folds of bacterial Pth1 being highly conserved. Similarly,
homologs from all three clades hydrolyze the bond between the 3’-adenosine and the
growing peptide chain. Therefore, the conservation in activity, structure, and important
residues could explain why the Vmax were similar across the clades. The chemistry of
the reaction does not change.
In contrast, the large differences in Km and Kcat/Km values were observed. Km
values have been related to the affinity of Pth1:bulk peptidyl-tRNA complex formation
while Kcat refers to the turnover rate (Robinson, 2015). Kcat/Km is related to the catalytic
efficiency of an enzyme. EcPth1 had the highest Km value out of all the homologs tested,
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while Clade 2 and Clade 3 homologs had lower Km values. This relative trend agreed
with previous studies (Giorgi, 2011; Schmitt, 1997; Goodall, 2004). Analyses with partial
substrate showed EcPth1 had a Km consistently between 5 – 6 μM. However, previous
kinetics studies using N,N-diacetyl-lysyl-tRNALys had greater substrate affinity and
better turnover numbers and catalytic efficient than with bulk peptidyl-tRNA. Previous
experiments using partial substrate found EcPth1 to have a Kcat of 1.0 – 3.6 s-1 and
Kcat/Km to be ~0.5 μmol-1*s-1. As only a relative comparison can be made, it could be
inferred the lower substrate affinity and catalytic efficiencies could arise for a greater
specificity to specific tRNA species. Previous studies determined that peptidyl-tRNAs do
not accumulate at the same rate with tRNALys having 75% of its cellular concentrations
accumulating as peptidyl-tRNA rapidly (Menninger, 1978). The family of tRNAs
consisting of aspartate, histidine, phenylalanine, threonine and valine accepting tRNAs
accumulated the fastest (Menninger, 1978). Not inconsequentially, many of these
residues are common at the start of many E. coli protein amino acid sequences (CruzVera, 2000). The fact that so many ribosome stalling residues are at the beginning of
many E. coli protein sequences has led to the suggestion that ribosome stalling could be a
means to ensure enough tRNA are present for translation to occur (Cruz-Vera, 2000).
Likewise, peptidyl-tRNA accumulation and starvation would be noticed much more
quickly with more commonly used tRNAs. Therefore, it seems likely there would be a
greater affinity for the more rapidly accumulating peptidyl-tRNAs and ribosome stalling
is a way to check and maintain translational health (Menninger, 1978; Cruz-Vera, 2002).
For example, while EcPth1 will hydrolyze prolyl-tRNAPro, it does so much more slowly
and less efficiently than dipeptide - hexapeptide tRNALys until a concentration threshold
74

of Pth1 was met (Janssen, 2009). As such, this reduction in Km, Kcat, and Kcat/Km could
also be a reflection that at higher in vitro substrate concentrations, Pth1 would take
longer to hydrolyze peptidyl-tRNA which Pth1 has lower affinity or Pth1-concentration
dependent peptidyl-tRNA species such as prolyl-tRNAPro.
While very few kinetics studies of any Clade 2 or 3 homologs exist outside this
current project, MtuPth1 and SaPth1 were previously shown to have a K m of 0.7 μM
and 2.8 μM, respectively (Bal, 2007; Bonin, 2002). Km values from this current project
and previous studies clearly showed the Clade 1 homolog, EcPth1, had less affinity to
peptidyl-tRNA than Clade 2 and Clade 3 homologs. Conversely, Clade 3 homologs had
the lowest Km values. As such, Clade 3 homologs consistently showed more favorable
binding to bulk peptidyl-tRNA than Clade 1 and Clade 2.
Clade 2 being an intermediate clade of Clade 1 and Clade 3 was increasingly
observed throughout this project. MtuPth1 had greater substrate affinity than Clade 1,
but lower substrate affinity than Clade 3 homologs. This trend was also seen in mixed or
indeterminate gram status, solubility yields, and inhibition profiles. MtuPth1’s substrate
affinity was more similar to Clade 3 than to Clade 1.
Likely, differences in substrate affinity and clade specific gate loop motifs caused
the differences seen in inhibition profiles across phylogenetic space. Substrate affinity
could also account for the increased incidence of broad spectrum and clade-specific
inhibition seen in Clade 1 homologs. Based on this data, EcPth1 would have less
favorable binding to peptidyl-tRNA. This could potentially allow for greater inhibition
as EcPth1 would require greater peptidyl-tRNA concentrations to reach saturation. As
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such, EcPth1 would have more enzyme available to bind more favorable substrates. As
such, greater levels of inhibition. It seemed likely that other Clade 1 homologs would also
have lowered substrate affinity like EcPth1 based on the high degree of conservation and
shared inhibition characteristics. Moreover, narrow spectrum inhibition was seen as
substrate affinity increased in Clade 2 and Clade 3. Based on this data, Clade 3 homologs
were more saturated and had greater substrate affinity than Clade 2 and Clade 3. As such,
Clade 3 homologs were less susceptible to inhibition, and any inhibitory compound(s)
would likely have to provide more favorable Pth1 binding than peptidyl-tRNA. Similarly,
SaPth1 E99P possessing the gate loop mutation had half the substrate affinity of wildtype
SaPth1 suggesting, at least in part, the gate loops involvement in substrate affinity. The
most likely explanation for this would be the exchange of a flexible aspartate residue to a
rigid proline residue not allowing for wider lid opening or widening of the catalytic
pocket.
One possible explanation for differences in substrate affinities could be due to the
phylogenetic gram-specificity and gram-specific tRNA modifications. tRNA
methylation, 1-methyladenine, and modifications were seen in Clade 2 and Clade 3, but
not present in Clade 1. In addition, some mycobacterial species, such as M. smegmatis,
are known to lack ribothymidine in their TψC arm (Klagbrun, 1972; Vani, 1979).
Previous models have suggested Pth1 tightly interacts with the TψC arm and plays a role
in substrate recognition (Hames, 2014). Outside of the TψC arm and 3’-CCA acceptor
stem, Pth1 interaction with peptidyl-tRNA has not been noted (Hames, 2014). As such,
tRNA methylation in the TψC arm of peptidyl-tRNA could aide in peptidyl-tRNA
recognition by Clade 2 and Clade 3 Pth1s similar to other tRNA modifying enzymes.
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Past results found that tRNA mimics missing the TψC arm showed EcPth1 had 10-fold
less substrate affinity, but retained the ability to hydrolyze peptidyl-tRNA (Giorgi, 2011).
Furthermore, Pth(rap) mutant harboring R133A mutation had significantly lowered
specific activity. Mutants possessing both R133A and K105A lacked both recognition of
the 5’-phosphate of peptidyl-tRNA and loss of specific activity suggesting both were
involved in substrate recognition. While 1-methyladenine is only found at A22 and A58
of tRNA in bacteria, 1-methylguanine or 2’-O-methyluridine modifications are present in
or near the 5’-tRNA acceptor stem from some gram positive not present in gramnegative species (Boccaletto, 2017). Because peptidyl-tRNA is bound at the 5’- and 3’acceptor stem, wider lid loop and catalytic pocket opening could be required to
accommodate for the presence of these tRNA modifications as the significant loss of
substrate affinity caused by a gate loop mutation might indicate (Fromant, 1999). Based
on the available data, the current hypothesis is that methylation in both the TψC arm and
the 5’-acceptor stem affect substrate affinity in Clade 2 and Clade 3 homologs. However,
without a high-resolution bound Pth1:peptidyl-tRNA structure, this remained highly
speculative. Further work would be needed to resolve tRNA methylations role, if any, in
Pth1 recognition or substrate affinity.
In conclusion, the chemistry of the reaction does not change across phylogenetic
space. In contrast, Km values were different. EcPth1, the Clade 1 homolog, had the
lowest affinity for peptidyl-tRNA based on results from current and previous projects.
MtuPth1 was kinetically intermediate of the Clades 1 and 3 homologs once again. This
further supported previous evidence found in the inhibition screen and biochemical
characterization that MtuPth1was the intermediate clade. The Clade 3 homologs had the
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greatest affinity for substrate and the fastest Vmax of the enzymes tested so far when bulk
peptidyl-tRNA was used. These differences could account for the phylogenetic
characteristics seen during the NPPE inhibition screen. Furthermore, the evidence from
phylogenetic analysis and kinetic characterization that tRNA methylation in the TψC arm of
peptidyl-tRNA could play a role in substrate affinity or recognition as previous models have
suggested. However, these results should be expanded to more Pth1 homologs across
phylogenetic space and peptidyl-tRNA substrate from a gram-positive species to confirm the
emerging kinetic trends due to the limited number of homologs tested.
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Chapter 5

Nucleotide inhibition of Pth1

5.1 Background
Nucleotide and nucleoside analogs were previously found to bind to helices 5
and 6 of MtuPth1 (Kabra, 2016; Giorgi, 2011). No activity assays were done in
conjunction with these studies. Therefore, it remained unknown whether nucleotides or
nucleotide analogs would actually have an inhibitory effect on any Pth1 homolog.
Pth1 was shown to complex with peptidyl-tRNA at the 3’-CCA acceptor stem
based on low-resolution small angle neutron scattering (Hames, 2014). Virtual docking
screens also determined inhibition likely occurred by interaction with residues within the
catalytic pocket (Harris, 2011). This study was conceived and undertaken to address the
question if nucleotide species themselves were inhibitory based on the structural data
from the previous SANS bound complex by testing nucleotides and nucleosides for
inhibition against Pth1 homologs.
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5.2 Results and Discussion
This current project initially screened EcPth1 inhibition against adenosine and
adenosine phosphates. Of the adenosine species, only adenosine triphosphate was found
to be weakly inhibitory in vitro. However, EcPth1 was found to be inhibited by ATP at
eukaryotic concentrations. Thus, nucleotide inhibition against homologs from Clade 1
and Clade 3 were extended to include other nucleotides and nucleosides. Sixteen
nucleotide species were tested for inhibitory activity against EcPth1, StPth1, and SaPth1.
The sixteen nucleotides tested were: adenosine, adenosine monophosphate (AMP),
adenosine diphosphate (ADP), adenosine triphosphate (ATP), cytidine, cytosine
monophosphate (CMP), cytosine diphosphate (CDP), cytosine triphosphate (CTP),
guanine, guanine monophosphate (GMP), guanine diphosphate (GDP), guanine
triphosphate (GTP), uridine, uridine monophosphate (UMP), uridine diphosphate (UDP),
uridine triphosphate (UTP). Following initial qualitative screen against all sixteen
nucleotides, those nucleotides which exhibited inhibition against EcPth1, StPth1 and
SaPth1 were furthered screened to determine an IC50 value for that homolog, as seen in
Figure 5.1.
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Figure 5.1 Nucleotide inhibition of bacterial Pth1 homologs: Both EcPth1 and SaPth1 were
inhibited by both ATP and GDP. Each had IC 50 values of 5 mg/mL and 10 mg/mL for ATP and
GDP, respectively. StPth1 was only inhibited by GDP with an IC 50 value of 2.5 mg/mL.

5.2.1 ATP inhibition
In vitro reactions containing 30 μM Pth1, 30 μM peptidyl-tRNA, and 4 μL ATP.
ATP concentrations were varied from 20 mg/mL to 0.63 mg/mL utilizing a 1:1 serial
dilution prior to the 4 μL ATP addition. EcPth1 and SaPth1 were both inhibited by ATP
in vitro. Interestingly, StPth1 was not inhibited by ATP.
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Figure 5.2 ATP Inhibition of EcPth1: A. Urea-PAGE of EcPth1 with ATP at decreasing
concentrations. B. Bar graph determination of EcPth1: EcPth1 was inhibited by ATP with an IC 50
of 5 mg/ml ± 0.95 mg/mL ATP. These results were similar to those of SaPth1.

5.2.1.1 EcPth1 ATP inhibition
Inhibition screens to determine an IC50 value were determined for EcPth1. As can
be seen in Fig 5.2, EcPth1 had an IC50 value of 5.0 ± 1.0 mg/mL. Pth1 activity did not
fully return even at the lowest ATP concentrations tested. This was likely due to lower
concentrations of ATP needed to achieve the return to activity. This seemed likely as
SaPth1 was not inhibited by 0.6 mg/mL ATP and all the GDP inhibition curves
approached zero. In the future, concentrations of 0.3 mg/mL or lower should be tested
against EcPth1 to verify this hypothesis. Importantly, 0.6 mg/mL ATP (1.2 mM ATP)
and above was within the eukaryotic physiological concentrations range of 1 mM to 10
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mM ATP (Traut, 1996). This was also within known bacterial concentration of ATP.
Previous quantitative ATP fluorescent based experiments established a median
concentration of 1.54 mM ± 1.22 mM (or 0.78 mg/mL ± 0.62 mg/mL) in E. coli
(Yaginuma, 2014). Using the median value of 1.54 mM, the IC50 value of 5.0 ± 1.0
mg/mL was 6.4 times higher than intracellular ATP concentrations meaning EcPth1 was
minorly inhibited by ATP. Therefore, at physiological eukaryotic concentrations of ATP,
EcPth1 will not be fully active.

Figure 5. 3 ATP inhibition of S. aureus Pth1: A. Urea-PAGE of SaPth1 with ATP at decreasing
concentrations. B. SaPth1 had an IC50 value of 5.0 mg/mL ± 1.4 mg/mL ATP.
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5.2.1.2 SaPth1 ATP inhibition
SaPth1 was found to have an ATP IC50 equal to that for EcPth1 (e.g. 5 mg/mL
ATP). These results were performed until three matching IC50 values were determined.
This was to account for the standard deviation in obtaining the IC50 values seen in Fig
5.3. Therefore, ATP’s IC50 for SaPth1 was 5.0 ± 1.4 mg/mL. This was similar to EcPth1,
which also had an IC50 value of 5.0 ± 1.0 mg/mL ATP. Both SaPth1 and EcPth1 were
inhibited in vitro by eukaryotic physiological concentrations of ATP. Therefore, at
physiological eukaryotic concentrations of ATP, SaPth1 was not fully active like EcPth1.

5.2.1.3 StPth1 not inhibited by ATP
StPth1 was screened against ATP. However, there was no ATP inhibition against
StPth1 (Fig. 5.1). Previous data revealed high intracellular ATP concentration to be a
virulence factor for S. typhimurium infections. S. typhimurium was found to evade host
immune response by hiding in macrophages (Lee, 2012). S. typhimurium have evolved to
use macrophagic signals such as ATP and acidic pH to upregulate Salmonella
pathogenicity island-2 (SPI-2) responsible for the creation of a Salmonella-containing
vesicle (Anderson, 2017). This allowed S. typhi to escape autophagic and phagocytotic
processes within macrophages and served to increase the virulence of the bacteria.
Therefore, the lack of inhibition by StPth1 was potentially explained given that this is a
way for S. typhimurium to evade immune response. Importantly, S. typhimurium and S.
typhi have identical Pth1 amino acid sequences. Therefore, both S. typhimurium and S.
typhi Pth1 were not susceptible to ATP inhibition.
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5.2.2 GDP inhibition
Following the experimental method used for ATP inhibition, each homolog was
screened for GDP inhibition. All Pth1 homologs tested were inhibited by GDP at or near
eukaryotic physiological concentrations. Like ATP, there was larger deviation with
regards to StPth1, but little deviation between EcPth1 and SaPth1 in terms of their
respective IC50.

Figure 5.4 GDP Inhibition of EcPth1: A. Urea-PAGE of EcPth1 with GDP at decreasing
concentrations. B. EcPth1 had an IC50 of 10 mg/mL ± 2 mg/mL GDP. In contrast to EcPth1 IC 50
for ATP, only 5 % activity was seen at 0.6 mg/mL GDP.
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5.2.2.1 EcPth1 GDP inhibition
EcPth1 had an IC50 of 10.0 ± 2.0 mg/mL GDP. Standard deviation was
determined by the three in vitro inhibition screens and is reported in the error bars for
Figure 5.4. Unlike the IC50 curve for ATP, EcPth1 GDP screen did not show stagnation
from 0.6 mg/mL GDP – 1.3 mg/mL GDP with 5 % and 23 % inhibition, respectively. As
such, this inhibition curve did not require the fitting as with ATP. However, GDP
concentrations in both eukaryotes and bacteria were 10 – 100 times lower than ATP
(Traut, 1997; Buckstein, 2008). Therefore, this was not necessarily indicative that GDP
would be inhibit EcPth1 at physiological eukaryotic concentrations but showed that GDP
was weakly inhibitory against EcPth1.
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Figure 5.5 GDP Inhibition of SaPth1: A. Urea-PAGE of SaPth1 with GDP at decreasing
concentrations. B. SaPth1 had an IC50 of 10 mg/mL ± 1.6 mg/mL in vitro. The inhibition was 0.2
% inhibited at 0.63 mg/mL. Inhibition was almost complete at 20 mg/mL.

5.2.2.2 SaPth1 GDP inhibition
Similarly, SaPth1 also had an IC50 of 10.0 mg/mL ± 1.6 mg/mL against GDP.
These results were performed in triplicate and the standard deviation for each was
represented by the error bars in Figure 5.4. Like EcPth1, SaPth1 IC 50 for GDP was two
times that of its IC50 value for ATP. At 20 mg/mL GDP, SaPth1 was 98 % inhibited.
Alternatively, SaPth1 was only 0.2 % inhibited at 0.6 mg/mL. Like EcPth1, SaPth1 was
not fully active with both ATP and GDP.

Figure 5.6 GDP inhibition of StPth1: A. Urea-PAGE of StPth1 with GDP at decreasing
concentrations. B. StPth1 had an IC50 of 2.5 ± 0.4 mg/mL. StPth1 was only inhibited by GDP.
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5.2.2.3 StPth1 GDP inhibition
StPth1 was inhibited by GDP at an IC50 value four times lower than both EcPth1
and SaPth1. The IC50 value for StPth1 against GDP was 2.5 mg/mL ± 0.4 mg/mL. This
meant StPth1 showed more susceptibility to GDP than other homologs with regards to
the IC50, but still outside the physiological concentrations of S. typhimurium and
eukaryotes. StPth1 was 89% inhibited at 20 mg/mL GDP. At 0.6 mg/mL, StPth1 was
fully active.
5.2.3 ATP and GDP competitively inhibit Pth1
Ki was determined for ATP and GDP against both EcPth1 and SaPth1 in order to
determine inhibition type. Based on this analysis, which utilized the technique previously
described in chapter 4 to find a Km apparent (Km, app). From this Km, app, Ki could be found
by using the formula Km, app = Km (1 + [I]/Ki). Due to the increase in Km and Vmax being
unaffected by the presence of inhibitor, both ATP and GDP competitively inhibited
EcPth1 and SaPth1. As no kinetic data existed at this time for StPth1, Ki determination
was not carried out, but GDP likely is competitively inhibiting StPth1 given both SaPth1
and EcPth1 were also competitively inhibited by GDP.
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Figure 5.7 ATP and GDP Ki determination against E. coli Pth1 and S. aureus Pth1: Both ATP and
GDP do not affect the Vmax of the enzymes without inhibition (shown in black), but does reduce
the Km.

5.3 Conclusions
Small molecules, such as ATP and GTP, inhibited bacterial Pth1 homologs in
vitro. There were two schools of thought as to how Pth1 inhibition could occur in the
literature. It was previously predicted that peptidyl-tRNA binding occurred along
residues in helices 5 and 6 of Pth1 (Giorgi, 2011). The crux of the argument that Pth1
bound peptidyl-tRNA about helices 5 and 6 relied on the gate loop relied heavily on a
highly dynamic gate loop region. The evidence pointed to incorrect assumptions being
made about Pth1’s global and local dynamics (Kabra, 2017).
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In contrast, results published by Hames et al (Hames, 2014) showed Pth1
complexed with peptidyl-tRNA at the 3’-CCA acceptor stem. This low-resolution SANS
structure could only give the overall shape of a bound Pth1:peptidyl-tRNA complex, but
demonstrated binding occurred only about the 3’-CCA acceptor stem of peptidyl-tRNA.
Previous NMR structural studies in EcPth1 also supported Pth1 binding peptidyl-tRNA at the
3’-CCA acceptor stem (Giorgi, 2011). Moreover, the putative RNA-binding residues in
helices 3 and 4 were shown to specifically bind to the 3’-adenosine (Giorgi, 2011).

As such, any small molecule bound to helices 5 and 6 would be unlikely
inhibitors based on findings of the complexed SANS structure, NMR structural studies
and NMR dynamics studies. Likewise, virtual docking screens have shown that
inhibition of Pth1 would most likely occur in the catalytic pocket rather than helices 5
and 6. These virtual screens found small molecules that directly interact with or
indirectly block access to the catalytic residues would be the most likely inhibitory
candidates (Harris, 2011). The most likely scenario remained inhibition occurred via
disrupting the interaction between peptidyl-tRNA and putative RNA-binding residues
near helices 3 and 4 and/or catalytic residues in the catalytic cleft. For this reason,
inhibitory small molecules in this project, such as nucleotides or nucleosides, were
predicted to prevent peptidyl-tRNA hydrolysis via this mechanism rather than interacting
with helices 5 or 6.
It was discovered bacterial Pth1 was not fully active at eukaryotic concentrations
of ATP. While GDP inhibition was interesting, this finding was not nearly as significant
as ATP inhibition of the Pth1 homologs tested since GDP concentrations in both bacteria
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and eukaryotes were 200 μM or lower (Traut, 1997; Buckstein, 2008). Furthermore,
bacterial GDP concentrations were typically higher than for eukaryotic cells barring those
concentrations from malignant carcinomas (Traut, 1997). Human cells in particularly had
concentrations usually less than 100 μM GDP (Traut, 1997). On average, eukaryotic
physiological ATP concentration was two or more orders of magnitude greater than
physiological concentrations of GDP. As such, while GDP inhibits Pth1, these are not
within the physiological range of bacteria or eukaryotes.
Unlike GDP inhibition of Pth1 homologs, ATP inhibition against EcPth1 and
SaPth1 were in physiological range. Importantly, bacterial Pth1 was not fully active at
eukaryotic ATP concentrations. This result provided possible clues towards why higherordered eukaryotes, such as Homo sapiens, possessed multiple Pths and Pth1-like
domains within their genomes. Some credence for this hypothesis was garnered from the
phylogeny of HsPth1 in comparison to bacterial homologs. HsPth1 was more closely
related to HsPth2 than any bacterial homolog. Likewise, amino acid conservation was
only showed 40% similarity, at its best, with homologs from across phylogenetic space.
The characteristic α/β hydrolase fold and catalytic residues of HsPth1 were conserved,
but little else was shared between bacterial Pth1 homologs and HsPth1. Given this new
evidence, the current hypothesis was the complexity of the eukaryotic tRNA recycling
system would be able to compensate for HsPth1 inhibition. Further work was needed to
determine if nucleotides are inhibitory against HsPth1 or HsPth2. Based on the available
data, HsPth2 was hypothesized to not be inhibited by nucleotides, specifically ATP.
StPth1 was only inhibited by GDP. S. typhimurium and S. typhi had the same
copy of Pth1. Therefore, both S. typhimurium Pth1 and S. typhi Pth1 were not inhibited
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by ATP. Several studies have determined high ATP concentrations to be virulence
factors for S. typhimurium infections in vivo. ATP upregulated Salmonella pathogenicity
island II which helped S. typhimurium escape the macrophage in a vesicle. As such, ATP
being a virulence factor for the escape and survival of S. typhimurium could provide a
potential explanation as to why StPth1 was not inhibited by ATP as Pth1 activity is
required for cell survival.
In conclusion, this current project established that bacterial Pth1 was inhibited by
GDP. Likewise, Pth1 was not fully active at physiological ATP concentrations except for
StPth1. This evidence pointed to a possible evolutionary reason why eukaryotes have
multiple Pth1-like domains and orthologous Pth enzymes. Pth1 inhibition caused by
increasing nucleotides concentration would create a need for an orthologous enzymes to
perform the same vital task of recycling peptidyl-tRNA.

92

Chapter 6

Conclusions and Future Work

6.1 Conclusions
Past studies established Pth1 as a promising drug target to combat antibiotic
resistant bacterial infections. Without Pth1, bacterial cells would undergo tRNA
starvation and die. Loss of Pth1 function caused cell death in E. coli, B. subtilis, and
M. tuberculosis. Therefore, Pth1 was found to be vital to bacterial survival, making
it a viable drug target. Eukaryotes, unlike bacteria, possessed multiple Pths and Pthlike domains. Alternatively, both Pth1 and Pth2 were found to be non-essential in
yeast. Importantly, HsPth1 was much more closely related to HsPth2 than any
bacterial homolog. Thus potential for selective inhibition of bacterial Pth1 may be
possible, supported by the findings hereing. Further, several current antibiotics have
targeted the ribosome and protein biosynthesis. As such, this has been a proven
strategy in combatting bacterial infections. Pth1 would have a distinct
stoichiometric advantage over targeting the ribosome alone since there were 1,3000
Pth1/cell compared to 10,000 ribosomes/cell in bacterial cells (Cruz-Vera.
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2000). Thus Pth1 is a promising new antibiotic target and the finding herein
advance Pth1 as a novel antibiotic target.
While much of the previous literature focused on EcPth1, to ascertain the
similarities and differences between homologs, this study sought to uncover the impact
phylogeny had on enzymatic behavior. The characteristics of six bacterial homologs
within their respective phylogenetic clades and across phylogenetic space were
investigated. This was the first project to explore these differences in a systematic way.
Based on these findings, it can be concluded that bacterial Pth1 homologs did not behave
the same with regards to qualitative biochemical characteristics. Moreover, quantitative
differences were observed in kinetics and natural product inhibition.

6.1.1 Phylogenetic clades
Three distinct phylogenetic clades of Pth1 emerged from multi-alignment
sequencing that behave differently from one another as noted in Figure 3.1. Importantly,
the phylogenetic clades did not behave similarly. Clade 1 homologs were qualitatively
easier to express and purify than Clade 2 or Clade 3 (Figure 3.3). Clade 3 homologs
required considerable optimization with their respective growth conditions to yield a
minimal amount of soluble purified protein. Clade 3 homologs were aeration rate and
IPTG-concentration dependent in their growth. While the Clade 2 homolog MtuPth1 did
not express as well as Clade 1 or Clade 3 homologs, the conditions for this homolog did
not require optimization. As such, MtuPth1 was qualitatively easier to purify producing
more soluble protein than Clade 3 Pth1 homologs. This also explained why most of the
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crystal structures within the PDB were elucidated using Clade 1 Pth1 homologs, and
why Clade 2 and Clade 3 had considerably fewer crystal structures in the PDB.
This study also demonstrated the differences between, and sometimes within,
clades manifested in differences in their respective inhibition profiles (Figure 3.7), small
molecule/nucleotide inhibition (Figures 5.1, 5.2 and 5.3) and their kinetics (Figures 4.7
and 4.8). This dispelled the previous assumption that all Pth1s would behave the same.
The differences between phylogenetic clades could be potentially exploited as an
antibiotic drug target to provide selective inhibition of individual Pth1 homologs in the
future.
The phylogenetic clades fell across gram-specific lines (Figure 3.1). Clade 1 Pths
were derived from gram-negative bacteria, such as E. coli, P. aeruginosa, and S.
typhimurium. Clade 3 Pth1 homologs came from gram-positive species such as S.
aureus, B. cereus, and S. pyogenes. Clade 2 Pth1s came from bacterial species that had
mixed or were impervious to gram stain. Gram-positive and mycobacterial species have
tRNA and rRNA methylation not observed in gram-negative bacteria (Klagbrun, 1972;
Vani, 1979; Bocchetta, 1998; Liu and Douthewaite, 2002). Specifically, tRNAs from
gram-positive and mycobacterial possessed 1-methyladenine at A58 in the TψC arm of
tRNA (Klagbrun, 1972; Vani, 1979). Recognition of tRNA modifications along the TψC
and 5’-acceptor stem of peptidyl-tRNA could have played a role in the differences in
their respect Kcat, Km and Kcat/Km (Table 4.3). However, some mycobacterial species,
such as M. smegmatis, are known to lack ribothymidine at T54 (Vani, 1979). Therefore,
Clade 2 Pth1 homologs lacking in ribothymidine but possess 1-methyladenine appear to
not only be intermediate of Clade1 and Clade 3 in their gram status, kinetics and
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inhibition profiles (Figure 3.7), but also the methylation or modifications of tRNA.
Furthermore, other translational systems also show gram-specificity when processing,
transferring or charging tRNAs. For instance was also found in 23S rRNA, which is vital
for peptidyl-tRNA binding to the P-site in the ribosome (Bocchetta, 1998). Gramnegative bacteria possessed guanine methylation at G745 in 23S rRNA; while grampositive bacteria were methylated at G748 in 23S rRNA (Liu and Douthewaite, 2002).
Therefore, it seemed probable that tRNA methylation also was responsible for the gramspecificity seen in this project.
Importantly, when the gate loop regions had more flexible residues as seen in
Clade 2 and Clade 3 homologs (Figure 3.4), substrate affinity and catalytic efficiency
was better. When one of these residues was mutated to a rigid proline, catalytic
efficiency and substrate affinity of SaPth1 decreased by half, but solubility and ease of
purification increased. As such, the gate loop region of Pth1 played a much larger role in
being determinate of clade characteristics than previously reported.

6.1.2 Narrow spectrum inhibition possible
Narrow spectrum inhibition was observed in the NPPE inhibition screen. Broad
spectrum and clade-specific inhibition was also present to varying degrees, but broad
spectrum antibiotics hasten antibiotic resistances (Fair and Tor, 2014). Clinicians have
been moving away from broad spectrum antibiotics due to the increased incidence of
antibiotic resistant when broad spectrum antibiotics are used (Fair and Tor, 2014). As
such, any new antibiotics and antibiotic drug targets should be narrow spectrum. The
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possibility of narrow spectrum inhibition seen in this study makes Pth1 a promising drug
target. Similarly, the differences between the clades further highlighted the differences
and the potential for selective inhibition of individual Pth1 homologs. Clade 1 Pth1s were
more susceptible to NPPE inhibition and had significantly more broad spectrum or clade
specific inhibition compared to Clade 3 homologs (Figure 3.7). Clade 3 homologs were
largely narrow spectrum and showed that individual Pth1s could be targeted in vitro. As
with yield of soluble protein and tRNA modifications, the Clade 2 homolog, MtuPth1,
was intermediate in terms of its inhibition profiles (Figure 3.7). Clade 2 (MtuPth1)
inhibition profile contained broad spectrum or clade-specific inhibition only seen in
Clade 1 and Clade 2. Conversely, MtuPth1 shared narrow spectrum inhibition with Clade
3 homologs. These finding reinforced that each homolog behaved differently. It would be
expected that the same NPPE would cause inhibition in all homologs if they behaved the
same or similarly, but there was only a few that produced broad spectrum inhibition.
Likewise, while clade-specific inhibition was observed in some clades, this was not
observed in Clade 3 homologs. This showed even further promise for the possibility of
narrow spectrum inhibition of an individual homolog if the component(s) of the NPPE
causing inhibition were inhibited. As such, the NPPE displaying the most potent
inhibition against Pth1 homologs in vitro should be screened against their respective
bacteria to determine the minimum inhibitory concentration (MIC) and any in vivo Pth1
inhibition.
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6.1.3 Nucleotide inhibition demonstrates small molecule inhibition possible
These results showed that small molecule inhibition against bacterial Pth1
homologs was possible. Apart from StPth1 and ATP, all three homologs were inhibited
by the small molecules, ATP and GDP (Figure 5.1). These findings gave even further
credence to the well-established role of ATP in S. typhimurium pathogenicity. More
importantly, the insusceptibility of StPth1 to ATP demonstrated that even within
phylogenetic clades each homolog can behave slightly different while still maintaining
much of the respective clade’s characteristics.
This further adds to the potential that even within clades selective inhibition of
individual Pth1 homologs could eventually be possible when combined with the narrow
spectrum inhibition seen in the NPPE inhibition screen. This new knowledge could be
used in conjunction with the inhibition profiles to target individual Pth1 homologs, thus
limiting the role broad spectrum antibiotics play in the development of antibiotic
resistances (Fair and Tor, 2014). Thus, this study established that small molecule
inhibition was possible across phylogenetic space.
At eukaryotic ATP concentrations, bacterial Pth1 was not fully active apart from
StPth1 (Figure 5.1). This finding lent further support that inhibition of HsPth1 could
potentially be compensated for by orthologs, such as HsPth2, within the eukaryotic tRNA
recycling system. Previous studies also showed the non-essentiality of Pth1 in lower
ordered eukaryotes. This could potentially explain why the multicomponent tRNA
recycling system seen in eukaryotes was more complex than their bacterial counterparts.
Therefore, it has been hypothesized that HsPth2 would not be inhibited by ATP as both
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the structure and mechanism are different than Pth1 homologs. Further testing would be
required to confirm this hypothesis.

6.1.4 Kinetic differences
Homologs across phylogenetic space showed very little deviation in their Vmax.
As structure and key catalytic residues were highly conserved across phylogenetic space,
Vmax being within less than 1 μmol/min of each other was indicative that their chemistry
was unchanged. Likewise, Kcat was similar for each homolog. However, the Km and
Kcat/Km parameters for each homolog across phylogenetic space, which measured Pth1’s
affinity for peptidyl-tRNA and catalytic efficiency, respectively, revealed stark
differences between Clade 1 and Clade 3 homologs. As seen with soluble protein yield,
gram status, and the NPPE inhibition screens, MtuPth1’s kinetic parameters were
intermediate of Clades 1 and 3. EcPth1, the Clade 1 homolog, had the slowest Vmax and
highest Km. As such, EcPth1 had the least affinity for bulk peptidyl-tRNA. Clade 3
homologs had the fastest Vmax and Km values approximately 20% lower. Therefore, the
Clade 3 homologs, SaPth1 and BcPth1 had 5.1 times and 6.3 times greater affinity for
bulk peptidyl-tRNA than EcPth1. MtuPth1, like Clade 3 homologs, had 3 times greater
affinity for peptidyl-tRNA than EcPth1.
While kinetic parameters were not directly comparable to previous results, the
overall trend observed with respective Km was consistent with past studies. The
differences in Km values could potentially be explained by gram-specific tRNA
methylation. This and past studies used modified, partial, or full peptidyl-tRNA substrate
99

largely derived from E. coli, lacking 1-methyladenine. Despite this, SaPth1 and MtuPth1
had consistently greater affinity for peptidyl-tRNA than EcPth1. Lack of differentially
methylated peptidyl-tRNA likely contributed to the faster Kcat and greater catalytic
efficiency in both Clade 2 and Clade 3 homologs seen in this project. Likewise, more
flexible residues in the gate loop region of these clades meant wider opening of the lid
loops and catalytic pocket required to accommodate for tRNA modifications. In
comparison, EcPth1 or PaPth1 which has a more inflexible Pro-Pro-Gly-Val motif
(Figure 3.4). This could very well account for the greater velocities, turnover rate, and
substrate affinity found in Clade 2 and Clade 3 homologs. Site-directed mutagenesis of
SaPth1’s gate loop provided evidence that this might alter the dynamics of the lid loop
opening and catalytic pocket widening. It is hypothesized at this time that both gate loop
residue accommodation for modified peptidyl-tRNAs and recognition of the TψC arm
could aid in substrate recognition, cleavage and specificity. However, at this time, it
remains uncertain whether substrate specificity would be affected by tRNA methylation.
As such, further work would be required to determine what role, if any, tRNA
methylation played in Pth1 substrate affinity.
Alternatively, Pth1’s substrate affinity could potentially explain other
phylogenetic characteristics, such as the inhibition profiles of the phylogenetic clades.
Clade 1 homologs were the most conserved of the clades and most susceptible against
NPPE inhibition, but Clade 1 had the least affinity for peptidyl-tRNA. Therefore, it
seemed probable that the decreased affinity for peptidyl-tRNA allowed for greater broad
spectrum and clade specific inhibition against NPPE. Conversely, Clade 3 homologs had
the most diversity in amino acid sequences, least susceptibility against NPPE inhibition,
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and greatest affinity for peptidyl-tRNA. This could account also account for the largely
narrow spectrum inhibition seen with this clade as Clade 3 homologs were more likely to
form Pth1:peptidyl-tRNA complexes than Clades 1 or 2. Likewise, MtuPth1 shared
commonality with both clades in its inhibition profile. While further kinetic analyses
across phylogenetic space would certainly be required to confirm these trends, these
findings further demonstrate that each clade behaves differently in terms of ease of
purification, inhibition profiles, or kinetic parameters. Importantly, these differences in
kinetic parameters and inhibition profiles could be exploited to provide small molecule
narrow spectrum inhibition in the future.

6.1.5 Gate loop mutations affect solubility and substrate affinity
Pth1 homologs required significant optimization to obtain soluble protein outside
of Clade 1 homologs. The Clade 3 homolog, SaPth1 required the most optimization to
obtain minimal yields of soluble protein. To improve solubility and purified yields issues
in SaPth1, site directed mutagenesis of the three residues in its gate loop motif was
performed individually to mirror the Pro-Pro-Gly-Val motif found in Clade 1 homologs.
SaPth1 E99P, Q100P and Q102V was mutated to match the P99, P100, and V102 gate
loop of Clade 1 homologs. Gly101 was not mutated in SaPth1 as this residue is known to
create temperature dependent Pth1s (Menninger, 1973). Past studies hypothesized that
the G101A mutation responsible for an EcPth1 temperature sensitive mutant caused it to
aggregate and become insoluble. Likewise, previous dynamics study showed the gate
loop of Pth1 to be static even with the highly flexible and dynamic Asp-Phe-Gly-Lys
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motifs found in MtuPth1 and M. smegmatis Pth1 (Kabra, 2017). Prior to the study by
Kabra et al (Kabra, 2017), it was hypothesized that the gate loop was highly dynamic.
However, the conservation of this structure forced normally dynamic residues like PheGly into energetically unfavorable folds. This current study found the E99P mutation to
increase solubility and soluble protein yield. This mutation also abolished aeration rate
and IPTG-concentration dependence normally seen in SaPth1. Importantly, the E99P
mutation decreased substrate affinity 2-fold (Fig 4.5). Proline is a more rigid residue that
doesn’t allow the dynamic opening of an aspartate in that position. It was hypothesized
this loss of substrate affinity was due to limited mobility in the lid loop and catalytic
pocket caused by the presence of a proline residue.
SaPth1 Q100P was not predicted to improve solubility. Q100 in the gate loop
forms a salt bridge with N153 in helix 5 of SaPth1. As expected, disruption of the salt
bridge yielded very little solubility. Q100 likely was structurally important and loss of
this residue could have caused SaPth1 to not fold properly.
SaPth1 Q102V did not negatively affect solubility. Under normal wildtype
SaPth1 growth conditions, this mutation was soluble. Yet, this mutation did not resolve
the aeration and IPTG concentration dependence when grown under normal EcPth1
conditions.
Based on this data, site directed mutagenesis of Asp/Glu to Pro in the gate loop
of Clades 2 and 3 should improve solubility like that of SaPth1. Therefore, Asp/Glu to
Pro in the first residue of the gate loop motifs of MtuPth1 could also be used to ease the
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difficulty in expressing and purifying these homologs for future kinetic and
structural studies and inhibition screens that could aid in drug discovery.

6.2 Future Work
This current study established three, distinct, gram-specific phylogenetic clades
with qualitative differences with respect to expression, solubility, and purification yields.
Mutating glutamate to proline in the gate loop increased solubility, abolished aeration
and IPTG concentration dependent growth of SaPth1. Inhibition profiles established
Clade 1 was more susceptible to NPPE, but also arrow-spectrum and broad spectrum
inhibition of Pth1 was possible in vitro. The Clade 2 homolog, MtuPth1, was
intermediate of Clade 1 and Clade 3 in terms of kinetics and inhibition. This study also
discovered Clades 2 and 3 homologs had greater affinity to bulk peptidyl-tRNA than the
Clade 1 homolog, EcPth1. Finally, physiological concentrations of ATP were inhibitory
to bacterial Pth1s. This could possibly be an evolutionary consequence of increased
intercellular concentrations of ATP in eukaryotes. Based on these conclusions, the
following future work studies were proposed.

6.2.1 Activity and affinity using B. subtilis peptidyl-tRNA possessing 1-methyladenine
Current evidence showed improved catalytic substrate affinity, turnover rate, and
catalytic efficiency was likely due to gate loop motifs causing greater local and/or global
dynamic movement and potential recognition of tRNA modifications. To determine
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whether the Clade 3 homologs had better catalytic efficiency and substrate affinity due to
tRNA modifications, repetition of the kinetics experiments on bulk peptidyl-tRNA from a
gram-positive species will be done. B. subtilis would be ideal to directly compared the
bulk peptidyl-tRNA from a gram-negative and gram-positive species as this is a nonpathogenic gram-positive bacteria. Importantly, B. subtilis tRNA are methylated with 1methyladenine at A58, and much is known about its Pth1 homolog. SpoVC, that was first
identified for its role in regulating sporulation (Young, 1976). However, SpoVC
knockout was also found to be vital to cell growth as well (Menez, 2002). A temperature
sensitive SpoVC mutant cell line, B. subtilis Spo285 (TS), was found to be
complimentary to E. coli C600 Pth TS cells (Menez, 2002). This cell line still possesses
vegetative and sporulation growth 30 °C, but sporulation was arrested at the nonpermissible temperature of 40 °C (Young, 1976). Likewise, the mechanism of
temperature sensitivity in B. subtilis Spo285 (TS) appeared to be like the peptidyl-tRNA
drop off seen in E. coli C600 Pth TS cells (Menez, 2002). Bulk peptidyl-tRNA extraction
from vegetative B. subtilis could be accomplished using the phenol:chloroform extraction
as previously described for E. coli C600 Pth TS cells with an additional phenol extraction
(Bishop, 1969). Furthermore, bulk peptidyl-tRNA had the additional benefit of being
recoverable from lyophilized B. subtilis spores (Bishop, 1969). This would require
optimization of growth and induction conditions, but rich media, such as LB broth, can
be used. If this cell line proved unattainable, previously established N-diacetyl-dilysyltRNALys could be purified as described by Schmitt et al. (Schmitt, 1997). Prior to
aminoacylation, half of the purified N-diacetyl-dilysyl-tRNALys would be methylated
with P. abyssi TrmI known to methylate A58 at the carbon 1 of adenosine. However, this
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would be laborious and time consuming. Extraction of bulk peptidyl-tRNA from B.
subtilis Spo-285 TS is preferred. In both cases, activity and kinetics against peptidyltRNA from gram-negative and gram-positive bacteria would be carried out as
described in this study to determine the effects of tRNA methylation.

6.2.2 SDM of gate loop in MtuPth1 and R. rickettsia Pth1 to increase solubility
Following the protocol set forth for SaPth1 E99P, Q100P, and Q102V, site
directed mutagenesis of MtuPth1 and R. rickettsia Pth1 (RrPth1) gate loop to improve
both expression and soluble protein yields. M. tuberculosis, responsible for tuberculosis,
and R. rickettsia, responsible for Rocky Mounted Spotted Fever, continued to be
medically relevant infections. Yet, MtuPth1 and RrPth1 have been historically difficult
to express and purify in laboratory conditions. Both the gate loop for MtuPth1 and
RrPth1 contain a negatively charged Asp or Glu in the first position of their respective
gate loop motifs. Mutation of MtuPth1 E101P and RrPth1 E97P would be beneficial in
not only future structural studies but also inhibition screens and kinetic analysis. This
would be cost saving in terms of both time and money to produce greater yields of
protein from a single batch.

6.2.3 MIC of NPPE in vivo
To expand upon the in vitro NPPE screen, macrobroth dilution minimum
inhibitory concentration (MIC) will be assayed to determine if the best 20 NPPE
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demonstrate in vivo inhibition in the bacteria from which the Pth1 homologs were
derived. Bacterial growth conditions will be assessed with growth curves and appropriate
rich media for each bacteria tested prior to MIC assays. 1:2 serial dilutions of the NPPE
will be placed in a culture with a final inoculum size of 5 x 10 5 cfu/mL, grown in
Mueller-Hinton Broth at 37 °C, and visually quantified for lowest concentration with no
visible bacterial growth (Balouiri, 2016). Each MIC will have a positive control of cells
and broth only, a negative control with cells, broth and an antibiotic, and a solvent control
with cells, broth and the solvent the NPPE was dissolved to assure inhibition was not
from the solvent used. Any positive results will be followed up with a solvent control,
cells only control, and cells transformed with their respective Pth1 homolog to determine
if the NPPE inhibition was due to Pth1 inhibition.

6.2.4 Determine kinetic parameters for Pth1s across the clades
Due to the limited number of homologs tested, expanding the homologs tested to
occupy greater phylogenetic space would be required to obtain a fuller understanding of
any differences in kinetics already observed. Yet, with only two Clade 1 and one Clade 2
homologs, it was difficult to ascertain if the kinetic parameters experimentally obtained
were outliers or truly representative of clade differences. Therefore, performing kinetic
analysis across phylogenetic space would be of benefit. This would be performed as was
with the five homologs and one mutant tested in this current study.
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6.2.5 Screen HsPth1 and HsPth2 for nucleotide inhibition
To test the hypothesis that eukaryotes possess multiple Pths due to rising nucleotide
concentrations, HsPth1 and HsPth2 will be screened for inhibition against all 16
nucleotides with a major focus on ATP and GDP inhibition as no other nucleotide species
showed inhibition against Pth1. HsPth2 was not expected to be susceptible to nucleotide
inhibition based on this current hypothesis. In order to accomplish this, HsPth1 and HsPth2
will be cloned into pKQV4 and pET28b vectors, respectively, in order to have
hexahistidine tagged HsPth1 and HsPth2 (His-HsPth1 and His-HsPth2).

107

APPENDICES

108

APPENDIX A:
LIST OF NPPE USED IN NPPE INHIBITION SCREEN

Table A.1: List of NPPE used in NPPE inhibition screen (Top 25 shown in Figure 3.7)

Natural Product Name

Solvent

1. Ardisia revoluta bark
2. Ardidendron vaillanti bark

Acetone
EtOH

3.
4.
5.
6.
7.
8.

Acetone
MeOH
CHCl3
EtOH
CHCl3
EtOH

Mandevilla veraguasenis
Inga sierra bark
Ardisia compressa
Exothea paniulata bark
Salacia liana bark
Lonchocarpus orotinus

9. AlDrymonia conchocalyx vine
10. Cestrum racemosum bark

EtOH
Acetone

11. Myorica sp “fuzzy leaf” leaf
12. Drypetes lasiogyna ver australasia
bark
13. Mallotus paniculate bark
14. Albizia adenocephalia
15. Ocistea floribunda Bark
16. Acacia aulacocarpa

Acetone
CHCl3

17. Conestegba xalapensis bark
18. Urera carcacasma

DMSO
EtOH

19. Psychotria parviflora
20. Sityrax argenteus bark

Acetone
CH2Cl2

21. Cinnamomum tonduzii bark
22. Syzygium johnsonii bark
23. Ocotea “los llamas” bark
24. Polysoma alangiacea bark

EtOH
EtOH
Acetone
CHCl3/EtOH

25. Grevilla lilliana bark
26. Neolitsea dealbata bark

CHCl3/EtOH
EtOH

27. Endiandra wolfei bark

CHCl3/EtOH
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EtOH
DMSO
Acetone
DMSO

28. Amphitecna haberi leaf

EtOH

29. Albizia julibrissin
30. Turpinia occidentalis leaf
31. Zanthoxylam bark
32. Conradina canescens

DMSO
CH2Cl2/MeOH
MeOH
MeOH

33. Agathis atropurpurea
34. Sweitenia mohogoni Bark
35. Byrsonima crassifolia bark
36. Ruyschia phyllandenia bark

DMSO
CH2Cl2
Acetone
EtOH

37. Conostegia xalapensis bark
38. Machaerium biovalatum bark
39. Ocotea “los llamas” leaf
40. Cryptocarya corrugata bark
41. Diospyres digyna bark
42. Galanthymine 0.1 mg/ml

Acetone
Acetone
DMSO
EtOH
EtOH
DMSO

43. Quercies insignis bark
44. Cedrela tonduzii bark
45. Lonchocarpus oliganthus bark
46. Coroton monteverdensis bark
47. Tapirira Mexicana bark
48. Verberina tarbacensis bark

CH2Cl2
Acetone
Acetone
CH2Cl2
EtOH
Acetone

49. Balapus australiana bark
50. Styphnolobium munteviridis bark
51. Myrcianthis “black fruit” bark

EtOH
CHCl3
CH2Cl2

52. Drypetes lasiogyna ver australasica
bark
53. Myorica sp “fuzzy leaf” leaf
54. Beilschiedia “concho blanco” bark
55. Bursera bark

EtOH

56. Bocconia fruitescens bark

Acetone
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Acetone
EtOH
CHCl3

APPENDIX B:
NONLINEAR REGRESSIONAL ANALYSES OF CLADE 2 AND
CLADE 3 HOMOLOGS

Figure B.1: Vo determination of MtuPth1: Initial Vo for MtuPth1 was determined at each bulk
peptidyl-tRNA concentration. The slope of the tangent line at time zero was equal to Vo for that
substrate concentration. Red, black and blue represents 28 μM peptidyl-tRNA. 56 μM, and 112
μM, respectively.
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Table B.1: Determination of initial M. tuberculosis Pth1 kinetic parameters

Table B.2: Determination of M. tuberculosis Pth1 Kinetic Parameters
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Figure B.2: Vo determination of SaPth1: Initial Vo for SaPth1 was determined at each bulk
peptidyl-tRNA concentration. The slope of the tangent line at time zero was equal to Vo for that
substrate concentration. Red, black and blue represents 28 μM peptidyl-tRNA. 56 μM, and 112
μM, respectively.
Table B.3: Determination of initial S. aureus Pth1 kinetic parameters
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Table B.2: Determination of S. aureus Pth1 Kinetic Parameters
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